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Abbreviations 
2D  two-dimensional 
AAPH  2,2'-azobis(2-amidinopropane) dihydrochloride 
ABTS  2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid 
ACEI  angiotensin-converting enzyme inhibition 
ATP  adenosine-5'-triphosphate 
CBG  cytosolic -glucosidase 
CC  column chromatography 
CoA  coenzyme A 
CVD  cardiovascular disease 
DCM  dichloromethane 
DMF  N,N-dimethylformamide 
DMSO  dimethyl sulfoxide 
EtOAc  ethyl acetate 
EtOH  ethanol 
FCS/FKS fetal calf serum 
Glc  -D-glucose 
HCl  hydrochloric acid 
HMBC  heteronuclear multiple-bond correlation 
HMEC  human microvascular endothelial cells 
HPLC  high-performance liquid chromatography 
HSQC  heteronuclear single-quantum correlation 
IC50  half maximal inhibitory concentration 
LOQ  limit of quantification 
LPH  lactase phlorozin hydrolase 
MeOH  methanol 
MMP  matrix metalloproteinase 
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NADH  nicotinamide adenine dinucleotide 
NADPH nicotinamide adenine dinucleotide phosphate 
NMR  nuclear magnetic resonance 
NOESY  nuclear Overhauser effect spectroscopy 
NOS  nitric oxide synthase 
NP  normal phase 
ppm  parts per million 
R2  coefficient of determination 
ROS  reactive oxygen species 
RP  reversed phase 
RT  room temperature 
SN2  bi-molecular substitution 
SULT  sulfotransferase 
TCA  tricarboxylic acid 
tR  retention time 
UGT  uridine 5'-diphospho-glucuronosyltransferase 
UV  ultraviolet 
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1 General Introduction 
1.1 Flavonoids and their Role in Plants 
Flavonoids are a group of plant secondary metabolites with more than 4000 described 
members (1999).1 They occur for instance in the epidermis of leaves and skin of fruits.2 The 
basic structure is a flavan skeleton, which consists of two six-membered aromatic rings, 
connected by a three carbon chain.2 Further oxidation and hydroxylation can form 
derivatives and thus the flavonoid family is divided into several subclasses (Figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Most of these flavonoids are glycosidated, which is, beside the substitution with hydroxyl 
groups, the reason for their hydrophilic properties.3 Nevertheless, also several more 
lipophilic conjugates with O-methyl or isopentyl groups are known.2 
Flavan 
Flavone 
Isoflavone 
Flavonol 
Anthocyanidin 
Flavanone 
Flavan-3-ol 
Figure 1: Generic structures of the major flavonoids
2
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The substitution with a sugar moiety is favoured at positions 3 or 7. Commonly found sugars 
are -D-glucose (Glc), α-L-rhamnose and -D-galactose. Further on, the glucose can be 
covalently bonded to a cinnamic acid moiety. In plants, flavonoids play an important role as 
pigments, to protect the plant from UV damage, in disease resistance and even for pollen 
development.4,2 The sub-
group of H2O-soluble 
anthocyanins forms some 
pigments with pink, red, 
violet, blue and purple 
colors (Figure 2). These 
pigments and their 
variations are, among 
others, generated by the pH-depended interactions of anthocyanins with so-called 
copigments. Copigments like flavonol glycosides are often part of inter- or intra-molecular 
complexes. But also self-association mechanisms, metal complexation and even covalently 
linked conjugates via malonic acid (in Allium schoenoprasum) have been reported.5,6 The 
consequence is an enhancement and higher stability of the color.6 Anthocyanins and their 
copigments are generally located in the vacuoles of the petal epidermal cells,5 but also cell 
wall bounded flavonol glycosides like the yellow kaempferol-3-rhamnosylgalactoside can be 
found in Eustoma grandiflorum, which cannot be regarded as copigment, due to the spatial 
separation.5 
1.2 Biosynthesis 
The biosynthesis of the flavonoids is described briefly starting from the photosynthesis, also 
regarding the ongoing discussions in literature concering the compartimentation of the 
different steps. 
Photosynthesis 
Located in the chloroplasts, the photosynthesis uses the energy of the light for an electron 
transport chain to generate reduction potentials and in particular NADPH and the energy 
store molecule ATP. These reduction equivalents and “energy carriers” are further used in 
the Calvin cycle to generate carbohydrates. During the Calvin cycle, a triose phosphate is 
formed (glyceraldehyde 3-phosphate    dihydroxyacetone-phosphate) which can either be 
Cyanidin-3-O-  
-D-glucoside         
(red to magenta 
Pelargonidin-3-O-
-D-glucoside 
(orangen to red) 
Delphinidin-3-O-
-D-glucoside 
(purple) 
Figure 2: Anthyocyanins and their color 
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Figure 3: Structure of 
malonyl-CoA 
transferred to the cytosol to support the synthesis of sucrose, or stay in the chloroplast to 
form starch.7 The final carbohydrate is not necessarily free glucose, but rather the 
disaccharide sucrose or the polysaccharide starch.7,8,9 
Glycolysis 
Glycolysis, which is localised in the cytosol and as well in plastids,7 produces energy in the 
form of ATP and the reduction equivalents NADH/H+. Starch, sucrose or dihydroxyacetone-
phosphate are all able to enter the glycolysis. The first two have to be hydrolyzed to its 
monomers, phosphorylated and in the case of glucose 6-phosphate, converted to fructose 6-
phosphate by hexose phosphate isomerase. Dihydroxyacetone-phosphate can enter the 
glycolysis directly after conversion to glyceraldehyde 3-phosphate (triose phosphate 
isomerase). One of the final products of glycolysis is pyruvate.7,8,9 
Synthesis of Malonyl-CoA 
In the next step, pyruvate from plastid located glycolysis undergoes decarboxylation to form 
acetyl-CoA. The latter is converted by acetyl-CoA carboxylase which involves the conjugation 
with hydrogen carbonate to form malonyl-CoA and is described as the first step in fatty acid 
biosynthesis.7,8,9 
The pyruvate from cytosol located glycolysis instead can pass the 
outer membrane of the mitochondria by free diffusion and the 
inner membrane by a specific carrier protein. In the mitochondria, 
pyruvate is also converted by the pyruvate dehydrogenase complex 
to form acetyl-CoA. In the next step, acetyl-CoA undergoes tricarboxyl acid (TCA) cycle which 
results in the formation of citrate. Citrate is transported to the cytosol via an antiporter 
(oxaloacetate). In the cytoplasm, citrate is converted to acetyl-CoA by ATP citrate lyase. 
Further on, acetyl-CoA is also transfered by acetyl-CoA carboxylase to form malonyl-CoA.7, 
10,11,12 
In general, acetyl-CoA can be found in at least four compartments namely in mitochondria 
(for the TCA cycle), in plastids (for de novo fatty acid biosynthesis), in peroxisomes (the 
product of β-oxidation of fatty acids) and in the cytosol.10,13 
Malonyl-CoA is one of the essential elements for the final flavonoid biosynthesis. 
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Figure 5: Structure of 
phenylalanine 
Figure 6: Structure of 4-
coumaroyl-CoA 
The Prechorismate Pathway or Shikimate Pathway 
The prechorismate pathway seems to be located exclusively in 
plastids14 but also isoenzymes can be found in cytoplasma. The 
starting materials for this sequence are phosphoenolpyruvate and D-
erythrose-4-phosphate. During glycolysis in the plastids, 
phosphoenolpyruvate is generated. Erythrose-4-phosphate is an 
intermediate in the regeneration of ribulose-1,5-bisphosphate (Calvin 
cycle) and in the pentose phosphate pathway. The reaction sequence is catalyzed by six 
enzymes and yields in chorismate.7,8,9  
The Postchorismate Pathway 
It is still not clear whether just plastids or even the cytosol has the ability 
of further conversion of chorismate to aromatic amino acids and thus, 
among others, phenylalanine.15 But most of the enzymes, which are 
necessary for this step (with the exception of cytosolic 
phenylpyruvate/4-hydroxyphenylpyruvate aminotransferase) were 
found in plastids.16 
The Phenylpropanoid Pathway 
Further enzymatic conversion of phenylalanine to cinnamic acid is 
catalyzed by phenylalanine ammonia-lyase (PAL), which can be 
found in the cytosol and is associated to the endoplasmic 
reticulum.17 Another enzymatic hydroxylation and conjugation 
with CoA leads to the formation of 4-coumaroyl-CoA.7  
 
 
 
 
 
Figure 4: Structure of 
chorismate 
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Synthesis of Flavonoids 
The association of 4-coumaroyl-CoA with three molecules of malonyl-CoA by the cytosol-
located chalcone synthase results in the formation of tetrahydroxychalcone, a compound 
which can already be described as submember of the flavonoid family.17 Following 
isomerisation to the flavanone naringenin, hydroxylation at position 3 and finally the 
generation of a C2-C3 double bond by the oxidoreductase flavonol synthase is one possible 
way for the synthesis of the flavonol kaempferol.7  
An additional glycosylation may also take place in the cytosol. The necessary enzyme, UDPG-
flavonoid glucosyl transferase was also detected at the cytoplasmic side of the endoplasmic 
reticulum.17 Overall it seems to be most likely and beneficial, that the final steps in flavonoid 
biosynthesis might be managed by an enzyme complex.17 
 
1.3 Flavonoids as Food Ingredients 
Flavonoid glycosides are present in several consumed food products and beverages like 
herbs, vegetables, fruits, tea and wine. The estimated daily flavonoid intake in humans is 
subject of some studies. But most of the investigations just regard about 2-5 flavonoids. For 
instance Hertog et al. (1993) report a daily intake of the potentially anti-carcinogenic 
flavonols quercetin, kaempferol, myricetin, together with the flavones apigenin and luteolin 
of 23 mg/day in the Netherlands.1 Considering, that Arts et al. (2001) have measured an 
average catechin intake of 50 mg/day in the Netherlands as well, makes the problem for the 
Figure 7: Final biosynthethic pathway to the flavonol kaempferol. Enzyme abbreviations: CHS, chalcone synthase; CHI, 
chalcone isomerase; F3H, flavanone 3-hydroxylase; FLS, flavonol synthase 
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Figure 8: Radical scavenging mechanism of kaempferol.
27
 DPPH: 2,2-
diphenyl-1-picrylhydrazyl 
investigation of total flavonoid intake obvious.18 The published averages differ between 
0.154 mg/day (4 isoflavones, USA) and 63.9 mg/day (4 flavonols, 1 flavone, 2 isoflavones, 
Japan) and therefore in a wide range, depending on several variables like analyte, 
geography, investigated food and possibly even age and gender of the participants.19,20 A 
value for an estimated total flavonoid intake for USA adults is 189.7 mg/day based on a 
database which contains the flavonoid content in foods.21 
 
1.4 Flavonoid Activities and their Structural Essentials 
In mammals, flavonoids are known to have, among others, anti-inflammatory, anti-oxidative, 
anti-viral, anti-thrombotic and 
spasmolytic activities.22 The 
knowledge on molecular mechanisms 
which are responsible for these 
activities is limited. Nevertheless, 
flavonoids have, depending on their 
hydroxyl pattern and presence of a 
carbonyl group, the ability of free 
radical scavenging (Figure 8, Figure 
9), metal ion chelating and enzyme 
inhibition. 
Some free radicals like the nitric 
oxide radical NO∙ or the superoxide 
radical O2∙
―, are generated 
deliberately in vivo by phagocytes.23 
The generation of nitric oxide also 
takes place in neurones and 
endothelial cells starting from L-
arginine by the enzym nitric oxide 
synthase (NOS).24,25 This compound 
plays an important role as intracellular signal, transcellular messenger and cytotoxic species 
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Figure 9: Catechol radical scavening activity
101
 
in the unspecific immune defence.26 But, as usual, the effect depends on concentration and 
environment and thus can also be 
destructive for DNA or important 
proteins. An excess of NO∙ can 
consequently cause cytotoxic and 
cytostatic effects.25 A further reaction 
of nitric oxide with the superoxide 
radical O2∙
― yields in the formation of 
peroxynitrite, which is directly 
cytotoxic.25 The free radical 
scavenging activity of flavonoids is 
based on the oxidizability of the B-
and C-ring. The oxidation of the 
compound and thus the reduction and deactivation of the nitric oxide- and other radicals 
proceeds in two steps.27 
Another part of the anti-oxidative effect of some flavonoids is the interaction with metal 
ions. The reason for this effect might be on 
one hand the chelating of the metal and a 
higher anti-oxidative potential of the resulting 
complex (e.g. quercetin/2Co2+, Figure 10).28 
On the other hand flavonoids can protect for 
instance low-density lipoprotein from directly 
Cu2+-induced oxidation by chelating this ion.29 
But in this context it has to be mentioned that 
these interactions depend strongly on the structure of the flavonoid and metal ion 
concentration. So even pro-oxidative effects of flavonoids are reported.30 
Flavonoids are also known to have enzyme inhibiting activity. At first, it can be assumed that 
either a complexation of the metal ion in the enzyme (if present) or an interaction with 
amino acids from the active side are responsible for this activity. Concerning the enzyme 
group of matrix metalloproteinases (MMPs) for instance, the inhibition is based on a 
Figure 10: Quercetin-cobalt-complex
28
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Figure 11: Influence of substitution pattern
37
 
hydrogenbridge bond and hydrophobic interactions in the zinc binding catalytic domain.31 
The chelation of the zinc ion can be discarded in this case, due to the distance from the ion 
to the flavonoid of more than 5 Å.31 Hydrogen bonds can also occur between the amino 
acids and the hydroxyl groups, preferentially at a catechol moiety of the flavonoid.31 
Hydrophobic interactions can be formed, among others, between the amino acid leucin and 
the chromon scaffold.31 These non-competitive inhibition of MMPs contributes to anti-
metastatic and anti-arteriosclerotic effects, which are reported for some flavonoids.32 Similar 
results have been published for the inhibition of the angiotensin-converting enzyme, which 
is one of the top-selling branches in the pharmaceutical industry. This enzyme is responsible 
for the maintenance of normal blood pressure via the conversion of Angiotensin I into 
Angiotensin II.33 Angiotensin II acts vaso-
contrictive and can thus cause hypertension 
and cardiovascular disease (CVD).34 Concering 
the flavonoids, the presence or absence of 
some structural elements changes the ACE-
inhibitory (ACEI) activity (Figure 11).34 In a 
study from Guerrero et al. (2012), Luteolin (17 
flavonoids were tested) showed the highest 
effect with an IC50 value of 23 µM. The 
essential structure elements are a double 
bond between C2 and C3, a carbonyl group in the C-ring, a free hydroxyl function at C3 and a 
catechol moiety at the B-ring. The latter is with distances of 2.1 Å (oxygen at C3’) and 4.3 Å 
(oxygen at C4’) to the zinc ion of the enzym within the range for chelation, but again, 
hydrophobic interactions and hydrogen bonds play a crucial role.34 Consequently, even if the 
ACEI activity of the flavonoids cannot measure up with those of the commercially available 
drugs, the common, regular dietary intake of flavonoids in a higher dose could prevent or 
reduce hypertension.34 
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1.5 Flavonoids containing Plants in Traditional Medicine 
Among the flavonoid subclasses, the flavonols are the most widespread.2 Kaempferol is 
beside quercetin the most important member of this group and can be found in some foods 
like i.e. endive, leek, broccoli, radish, grapefruit and black tea in higher concentrations.35,36 
Further on, significant yields of kaempferol and its conjugates can be found in several 
traditionally used medicinal plants: 
 Camptosorus sibiricus (Aspleniaceae), North China, treatment of vascular 
inflammation, diabetic complication and traumatism37 
 Stenochlaena palustris (Blechnaceae), Papua New Guinea, used as a contraceptive38 
 Cinnamomum osmophloeum (Lauraceae), Taiwan, treatment of inflammation, 
intestinal infections, astringent, diuretic and diabetic complications39 
 Epimedium sagittatum (Berberidaceae), People's Republic of China, coronary heart 
disease, chronic bronchitis, frequency/urgency of urination, aphrodisiac40 
 Ilex paraguariensis, mate tea (Aquifoliaceae), South America, choleretic, 
hypocholesteremic, anti-oxidant, hepatoprotective effects41 
 Momordica foetida, (Cucurbitaceae), East Africa, antimalarial activity42 
 Ginkgo biloba, (Ginkgoaceae), People's Republic of China, treatment of heart and 
lung dysfunctions, skin infections43 
 
Of course it has to be remarked, that this is only a short list of examples among several other 
plants and furthermore the healing properties may not be only the result of the kaempferol 
content. In general, it is improbable that the use in traditional medicine is attributed to one 
compound. But some studies have shown, that kaempferol has various pharmacological 
activities: anti-oxidant, anti-inflammatory, anti-microbial, anti-cancer, cardioprotective, 
neuroprotective, anti-diabetic, anti-osteoporotic, estrogenic/anti-estrogenic, anxiolytic, 
analgesic and anti-allergic.44 
 
Some more detailed information on kaempferol glycosides in Ginkgo folium, synthetic 
strategies, in vivo metabolism and pharmacology can be found at the beginning of each 
specific topic. 
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1.6 Objectives 
Kaempferol is beside quercetin one of the most common flavonols in vegetables and herbal 
medicines. Wherein the in vivo metabolism of quercetin is widely understood, the exact 
structures of in vivo kaempferol conjugates and their plasma concentration are unknown or 
not absolutely evidenced. 
The first aim of this thesis was to isolate kaempferol glycosides from two fractions of a  
Ginkgo folium extract, provided from Dr. Willmar Schwabe GmbH und Co. KG. A standard 
chromatographic scheme should be developed, which allows the facile isolation of 
compounds in sufficient amounts for in vivo pharmacokinetic investigations in rats with a 
certain dosage. 
Five expected metabolites of kaempferol should be chemically synthesized, in order to have 
reference substances for the analysis of the plasma samples. Therefore, synthetic pathways 
starting from the aglycone should be developed to yield in the formation of four kaempferol 
glucuronides and one kaempferol sulfate, wherein the latter is already described in 
literature. 
In the next step, the metabolites of kaempferol in rat plasma should be identified and 
quantified by HPLC-UV. Therefore some preparatory work has to be accomplished, which 
includes the development of a combined workup method for the plasma samples and a 
suitable chromatographic separation with regard to the recovery and the limit of 
quantification. 
Finally, some pharmacological data of kaempferol and its conjugates should be examined, 
with the focus on potential anti-oxidative, anti-proliferative and anti-inflammatory effects. 
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Figure 12: Gingko leaf
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2 Isolation and Quantification of Kaempferol Glycosides 
2.1 Introduction 
Ginkgo biloba LINNÉ (Ginkgoaceae) is described by Charles Darwin as ´living fossil´ due to little 
or no morphological changes in the past 100 million years.45 It belongs to the group of 
gymnosperms, is a dioecious plant and the only member of 
the Ginkgoaceae family. The tree has a grey bark, reaches a 
height of 30-40 m and has a diameter of 3-4 m. The plant is 
probably native in China and Japan and was cultivated in 
temples. Since the 18th century it can be found in european 
parks. Ginkgo folium consists of the green to yellowish 
whole leaves (4-10 cm). The leaf is characteristic and 
bilobate, fan-like and the venation is dichotomously and 
almost parallel (Figure 12).46,47,48 
At least eight kaempferol glycosides are known from literature to occur in Gingko folium. In 
Figure 13 the structures are presented. For the preparation of the extract, one can find 
different monographs, all using the powdered drug, which is processed as described briefly 
in the following : 
 U.S. Pharmacopoeia:   methanol, c(suspension) = 0.1 g/mL, reflux, 10 min 
 Chinese Pharmacopoeia: for flavonoids: methanol, c(suspension) = 0.1 g/mL, 
    reflux, 10 min 
for terpene lactones: 50% acetone, 
 c(suspension) = 0.025 g/mL, reflux, 3 h 
 Hong Kong Chinese Materia Medica Standards: methanol, c(suspension) = 0.1 g/mL, 
sonification, 30 min 
 European Pharmacopoeia: methanol, c(suspension) = 0.2 g/mL, 65 °C, 10 min 
 EGb 761® complies the monograph in the European Pharmacopoeia “Ginkgo dry 
extract, refined and quantified”: 60% acetone 
The indications listet in the chinese pharmacopoeia are: obstruction of collaterals by blood 
stasis, chest impediment and heart pain, hemiplegia caused by windstroke, cough and 
panting caused by lung deficiency and hyperlipidemia. 
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Figure 13: Kaempferol glycosides in Ginkgo folium 
3-O-(-D-Glucosyl)kaempferol
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3-O-(α-L-Rhamnosyl)kaempferol
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3-O-(6-O-(α-L-Rhamnosyl)--D-
glucosyl)kaempferol
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3-O-(2-O-(-D-Glucosyl)-                 
α-L-hamnosyl)kaempferol
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3-O-(2-O, 6-O-Bis(α-L-rhamnosyl)-              
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For the isolation of kaempferol glycosides, two flavonol glycosides enriched fractions of EGb 
761® were provided from the Dr. Willmar Schwabe GmbH and Co. KG. In the following, a 
combination of chromatographic methods was developed, which allows the isolation of 
some kaempferol derivatives for extract quantification and in vivo investigation. 
The standardized extract EGb 761® consists of about 22-27% flavonoid glycosides and 5-7% 
terpene lactones.49 The extract is the active ingredient in Tebonin® caplets and the scope of 
application covers disturbances of memory, concentration disorders, depressive state, 
dizziness, tinnitus and headaches.49 The corresponding aglycones of the flavonoids are 
mainly quercetin, kaempferol and isorhamnetin. The maximum daily recommended oral 
dosage for the extract in Tebonin® is 240 mg which is equivalent to about 3.2 mg/kg. 
In the present study, it has to be considered, that an administration of 3.2 mg/kg is not 
sufficient for an in vivo investigation in rats due to the different metabolic situation and the 
expected plasma levels of the metabolites would be with certainity under the limit of 
quantification (LOQ) using HPLC with UV detection, even if just a pure compound is 
administered and not the whole extract. 
In a comparable study, rats were treated with a dosage of 600 mg/kg of the extract, which 
yields to a maximum kaempferol concentration (aglycone) of 341 ng/mL after 8 hours.50 In 
the present study, not the extract should be used for administration, but different 
kaempferol glycosides in their pure form and depending on their content in EGb 761®. 
Consequently, the standardized extract has to be quantified concerning the isolated 
kaempferol glycosides.  
The pure compounds are further on used in the next step as reference substances for the 
quantification of the standardized extract. 
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2.2 Material and Methods 
2.2.1 Consumable Material 
2.2.1.1 Solvents 
 Acetone, EMSURE®, for analysis, Merck KGaA, 64271 Darmstadt, Germany 
 Ethyl acetate, for analysis, 99.99%, Acros, New Jersey, USA 
 H2O, deionised, further purified by membraPure, Astacus, MembraPure GmbH, 
Berlin, Germany 
 2-Propanol, EMSURE®, for analysis, 99.8%, Merck KGaA, 64271 Darmstadt, 
Germany 
 2-Propanol, ROTISOLV® HPLC, ≥ 99.9%, Carl Roth GmbH & Co. KG, 76185 
Karlsruhe, Germany 
 DMSO, SeccoSolv®, ≥99.9%, Merck KGaA, 64271 Darmstadt, Germany 
 Methanol, EMSURE®, for analysis, 99.9%, Merck KGaA, 64271 Darmstadt, 
Germany 
2.2.1.2 Naturstoffreagenz A 
 2-Aminoethyldiphenylborinate, 2 g dissolved in 200 mL MeOH, Fluka®, Sigma-
Aldrich Chemie GmbH, 89555 Steinheim, Germany 
 Polyethylene glycol 400, 10 g dissolved in 200 mL MeOH, Merck Schuchardt OHG, 
85662 Hohenbrunn, Germany 
2.2.1.3 TLC 
 TLC Silica gel 60 F254, Merck KGaA, 64271 Darmstadt, Germany 
 TLC chambers, Camag, Muttenz, Switzerland 
2.2.1.4 NMR 
 Bruker Avance 300, Bruker Corporation, Billerica, USA 
 Methanol-d4, 99.8%, Deutero GmbH, 56288 Kastellaun, Germany 
 NMR tubes, 507-HP, 203 mm, Norell, Landisville, USA 
2.2.2 Columns and Stationary Phases for Isolation 
 Flash-NP: SuperVarioPrep® D40, 46 x 186 mm, filled with stationary phase 
Geduran® Si 60 63-200 µm, 90 g, Merck KGaA, 64271 Darmstadt, Germany 
 Flash-RP: SuperVarioPrep® D40, 46 x 186 mm, filled with stationary phase RP18 
25-40 µm, 90 g, Merck KGaA, 64271 Darmstadt, Germany 
 Semipreparative HPLC: Knauer, Vertex, 16 x 250 mm, filled with stationary phase 
Eurospher-100 C18-7 µm, 14163 Berlin, Germany 
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2.2.3 Extract and Fractions 
The extract of Ginkgo folium and flavonoid enriched fractions were obtained from Dr. 
Willmar Schwabe GmbH & Co. KG. 
 Flavonol diglycosides enriched extract: PSC0148/B/Wo06-149-02, 35 g 
 Flavonol triglycosides enriched extract: PSC0148/B/Wo06-148-16, 100 g 
 Standardised Ginkgo folium extract: PSC0148/Ginkgo-Extrakt/ Ch.454 
2.2.4 Instruments 
 Flash: Spot Flash Liquid Chromatography, SPOT-System Ser.-No. 08-01-108, 
single-beam spectrophotometer, Interchim, 03103 Montlucon, France 
 Semipreparative HPLC: Varian ProStar, Model 210, diode array detector, Agilent 
Technologies Deutschland GmbH, 71034 Böblingen, Germany 
 Analytical HPLC:  
 Column: Hibar® 250-4, Purospher® STAR, RP18e (5 µm), Column No.: 
027444, Merck KGaA, Darmstadt, Germany 
 Precolumn: LiChroCART® 4-4, Purospher® STAR, RP18e (5 µm), Merck 
KGaA, Darmstadt, Germany 
 Pump: Hitachi L-2130, VWR, Darmstadt, Germany 
 Autosampler: Hitachi L-2200, VWR, Darmstadt, Germany 
 Column Oven: Hitachi L-2350, VWR, Darmstadt, Germany 
 Diode Array Detector: Hitachi L-2455, VWR, Darmstadt, Germany 
 Software, EZChrom Elite, Version 3.1.7, VWR, Darmstadt, Germany 
 Mass spectrometer: 
 TermoQuest Finnigan TSQ 7000, Thermo Fisher Scientific, Waltham, USA 
 Electrospray ionization (ESI) 
  
 Isolation and Quantification of Kaempferol Glycosides 
~ 26 ~ 
  
2.2.5 Isolation of Flavonol Diglycosides 
2.2.5.1 First Chromatographic Separation 
Instrument:  Flash chromatography 
Column:  Merck, SuperVarioPrep® D40, 46 x 186 mm, for 90 g Silica Si 60 
Stationary Phase: Merck, Geduran® Si 60 63-200 µm, 40 x 140 mm 
Mobile Phase:  A: EtOAc, B: acetone, C: H2O 
The solvents where exhaustively mixed in a separatory funnel; after 
phase separation, the upper phase was used for CC 
Application   3.0 g diglycoside extract + 4.5 g silica gel 
Fractionation:  52 min 
Gradient:  0-25 min: EtOAc: acetone: H2O ~ 6:2:0,7 
   25-40 min: EtOAc: acetone: H2O ~ 5:3:1 
   40-52 min: 100% MeOH 
Flow:   50 mL/min  
 88 fractions each 30 mL 
 
2.2.5.2 Second Chromatographic Separation 
Instrument:  Semipreparative HPLC 
Column:  Knauer, Vertex, 16 x 250 mm 
Stationary Phase: Eurospher-100 C18-7 µm 
Mobile Phase:  A: H2O, B: 2-propanol 
Application:  300 µL (H2O: 2-propanol 70:30), ~ 33 mg of F3 
Fractionation:  31 min 
Gradient:  0 min: 15% 2-propanol 
   25 min: 30% 2-propanol 
   25-27 min: 30% 2-propanol 
   29 min: 15% 2-propanol 
   29-31: 15% 2-propanol 
Flow:   5 mL/min  
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2.2.6 Isolation of Flavonol Triglycosides 
2.2.6.1 First Chromatographic Separation 
Instrument:  Flash chromatography 
Column:  Merck, SuperVarioPrep® D40, 46 x 186 mm, für 90 g Silica Si 60 
Stationary Phase: Merck, Geduran® Si 60 63-200 µm, 40 x 140 mm 
Mobile Phase:  A: EtOAc, B: acetone, C: H2O 
The listed solvents where exhaustively mixed in a separatory funnel, 
after phase separation, the upper phase was used for CC 
Application:  5.0 g triglycoside extract + 7.5 g silica gel 
Fractionation:  55 min 
Gradient:  0-10 min: EtOAc: acetone: H2O ~ 5:3:1 
   10-40 min: EtOAc: acetone: H2O ~ 5:4.5:2 
   40-52 min: 100% MeOH 
Flow:   30 mL/min  
 55 fractions each 30 mL 
2.2.6.2 Second Chromatographic Separation 
Instrument:  Flash chromatography 
Column:  Merck, SuperVarioPrep® D40, 46 x 186 mm, 90 g 
Stationary Phase: Merck, RP18 25-40 µm, 90 g,  40 x 115 mm 
Mobile Phase:  A: H2O, B: 2-propanol 
Application:  1.7 g F2 + 2.5 g RP18 
Fractionation:  33 min 
Gradient:  0 min: 15% : 2-propanol 
   22 min: 28%: 2-propanol 
   22-33 min: 2-propanol 
Flow:   30 mL/min  
 33 fractions each 30 mL 
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2.2.6.3 Third Chromatographic Separation 
Instrument:  Semipreparative HPLC 
Column:  Knauer, Vertex, 16 x 250 mm 
Stationary Phase: Eurospher-100 C18-7 µm 
Mobile Phase:  A: H2O, B: 2-propanol 
Application:  100 µL (H2O: 2-propanol 95:5), ~ 36 mg of F2 
Fractionation:  33 min 
Gradient:  0 min: 10% 2-propanol 
   24 min: 20% 2-propanol 
   24-27 min: 20% 2-propanol 
   30 min: 10% 2-propanol 
   30-33: 10% 2-propanol  
Flow:   7.5 mL/min  
 
2.2.7 Quantification of four Kaempferol Glycosides in EGb 761®  
2.2.7.1 Principles 
 Two times, 5.0 mg of each reference substance were dissolved in DMSO ≙ two 1st 
stock solution for each compound 
 60 µL of the 1st stock solution were diluted with 1940 µL of 7% aqueous 2-propanol ≙ 
2nd stock solution 
 Depending on the desired concentration, 75-260 µL of the 2nd stock solution were 
brought to the volume of 1 mL with 7% aqueous 2-propanol 
 One calibration curve based on six points 
 Only three points of each calibration curve are based on a single 1st stock solution 
 Three calibration curves for each reference substance 
 These three calibration curves were arithmetically averaged 
 The single calibrations curves are interday 
 Interday precision und intraday precision based on a single 1st stock solution 
 Three times, 5.0 mg of the standardized extract were dissolved in 3320 µL of 7% 
aqueous 2-propanol and 7.5 µL DMSO 
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2.2.7.2 Analytical HPLC for Extract Quantification 
Instrument:  Analytical HPLC 
Oven:   30 °C 
Thermo Unit:  4 °C 
Column:  Precolumn: LiChroCART® 4-4, Purospher® STAR RP-18e (5 µm) 
Main column: Hibar® 125-4, Purospher® STAR RP-18e (3 µm) 
Mobile Phase:  A: H2O + 0.1% TFA, B: 2-propanol  
Injection Volume: 20 µL  
Gradient/Flow: 0 min: 7% 2-propanol   0.7 mL/min 
   60 min: 20% 2-propanol  0.7 mL/min 
   70 min: 30% 2-propanol  0.6 mL/min 
   77 min: 30% 2-propanol  0.6 mL/min 
   80: 7% 2-propanol   0.6 mL/min 
   90: 7% 2-propanol   0.7 mL/min 
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2.3 Results and Discussion 
The aim of the isolation was to get kaempferol glycosides for the in vivo investigations and as 
references for extract quantification. A combination of chromatographic methods was 
developed to isolate these compounds from two flavonol-enriched subfractions of the 
extract EGb 761®. For the isolation of kaempferol diglycosides, two chromatographic steps 
were needed, whereas 3-O-(2-O, 6-O-bis(α-L-rhamnosyl)--D-glucosyl)kaempferol was 
isolated within three steps. The final purification was successful by use of a H2O/2-propanol 
gradient. The crucial separation of the kaempferol- from the isorhamnetin derivatives could 
not be achieved with H2O/MeOH or H2O/acetonitrile mixtures. The final assignment of the 
flavonol glycosides to the corresponding region on the TLC is depicted in Figure 14. 
At the beginning, the enriched extract was analyzed by TLC. It could be seen, that the 
addition of formic or acetic acid leads to a good separation on normal phase. Nevertheless, it 
was tried to avoid acid in the mobile phase, because hydrolysation can occur during the use 
of the rotation evaporator. 
Figure 14: NP-TLC of flavonol glycoside enriched extracts. Application: diglycoside-enriched extract; triglycoside-enriched 
extract. Mobile phase: EtOAc:acetone:H2O ∼ 5:3:1, 6 runs. Detection at 254 and 366 nm (bands 1-4); 366 nm after 
derivatisation with Naturstoffreagenz A (band 5 and 6) 
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A mixture of EtOAc, 
acetone and H2O 
showed a good 
separation on TLC. It 
was necessary to 
develop the TLC plate 
about six times, but 
this procedure results 
in a good separation of 
the compounds, which 
is exemplarily shown 
for the triglycoside 
enriched fraction in 
Figure 15. 
Consequently, different 
mixtures of these three solvents with varying elution strength were prepared for the first 
normal phase column chromatography. 
Isolation of Kaempferol Diglycosides 
The first separation with flash column 
chromatography visualized on TLC showed, after 
derivatisation with Naturstoffreagenz A, four 
fluorescent areas (366 nm) at an Rf value 
between 0.34 and 0.56 (Figure 16). The upper 
three have a greenish yellow fluorescens, which 
indicates one free hydroxyl group at the B-ring 
of the flavonoid and can thus be assigned, with 
regard to the metabolite spectrum of Ginkgo 
folium, possibly to kaempferol- and/or 
isorhamnetin derivatives.51 The lower, more 
orange spot can be associated to a flavonoid 
with two free hydroxyl functions at the B-ring.51 
Figure 15: Six times development on NP-TLC of the triglycoside-enriched extract 
compared to isolated substances. Application (bands 1—4): 3-O-(2-O, 6-O-bis(α-L-
rhamnosyl)--D-glucosyl)quercetin; triglycoside enriched fraction; 3-O-(2-O, 6-O-
bis(α-L-rhamnosyl)--D-glucosyl)isorhamnetin; 3-O-(2-O, 6-O-bis(α-L-rhamnosyl)--
D-glucosyl)kaempferol. Mobile phase: EtOAc:acetone:H2O ∼ 5:3:1 
   3  i8 13 18 23 28 33 38 43 48 53 58 63 68 73 78 83 88 
Kaempferol rutinoside 
Isorhamnetin rutinoside 
Kaempferol biloside 
Quercetin rutinoside 
 
Figure 16: NP-TLC after CC of the diglycoside enriched 
fraction. Mobile phase: EtOAc:acetone:H2O ∼ 5:3:1; 6 
developments; detection at 366 nm after derivatisation 
with Natursoffreagenz A. CC according to 2.2.5.1 
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Overall, the separation is not perfect, 
due to the overlap of the four spots from 
test tube 28-73. Nevertheless, it can be 
noted that a combination of the test 
tubes 18-38 would give a fraction of 
mainly the desired compounds (greenish 
yellow fluorescens) and avoids the major 
part of the quercetin glycoside. Further 
on, some more lipophilic ingredients 
could be separated from the kaempferol 
diglycosides, which allowed the 
subsequent use of reversed phase HPLC. 
With the application of a H2O/2-propanol 
gradient, a sufficient separation of the 
remaining flavonoid glycosides could be achieved (Figure 17). Beside the already expected 
flavonols, a myricetin glycoside could be isolated. Overall, five flavonol diglycosides were 
isolated, wherein two are kaempferol derivatives.  
tR = 17.83 
Myricetin 
rutinoside 
tR = 20.19 
Quercetin 
rutinoside 
tR = 23.19 
Isorhamnetin 
rutinoside 
tR = 25.33 
Kaempferol 
rutinoside 
tR = 27.60 
Kaempferol 
biloside 
Figure 17: Semipreparative HPLC chromatogram of the 
diglycosides at 349 nm. CC according to 2.2.5.2 
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Isolation of Kaempferol Triglycosides 
The flavonol triglycoside enriched fraction was first subjected to normal phase flash column 
chromatography, wherein some traces of remaining diglycosides with a medium Rf-value 
could be removed. In contrast, the separation form the orange fluorescent quercetin 
glycoside is unsatisfactory (Figure 18). 
 
 
 
 
 
 
 
 
An additional reversed phase flash column 
chromatography was accomplished with 
an H2O/2-propanol gradient. This step 
could remove the major part of quercetin 
triglycosides (fraction 8) from kaempferol- 
and isorhamnetin triglycosides (Figure 
19).  
The final purification step was again 
achieved by semipreparative HPLC 
(H2O/2-propanol gradient), which yielded 
in the isolation of the three flavonol 
glycosides (Figure 20). 
tR = 22.77 
Quercetin  
triglycoside 
tR = 26.21 
Kaempferol 
triglycoside 
tR = 25.08 
Isorhamnetin 
triglycoside 
Figure 20: Semipreparative HPLC chromatogram of the 
triglycosides at 349 nm. CC according to 2.2.6.3 
i4  7   10 13 16 19 i22 25 28 31 i34  37 40 43 46 49  52  55 
Kaempferol triglycoside 
Isorhamnetin triglycoside 
Quercetin triglycoside 
 
Diglycoside containing fractions 
 
Figure 18: NP-TLC after CC of the triglycoside enriched 
fraction. Mobile phase: EtOAc:acetone:H2O ∼ 5:3:1; 6 
developments; detection at 366 nm after derivatisation 
with Natursoffreagenz A. CC according to 2.2.6.1 
4   i5    6   7   8   9  10  11 12 13 1 4 15  16  17 18 19 20  21 22 
Kaempferol triglycoside 
Isorhamnetin triglycoside 
Quercetin triglycoside 
 
Diglycoside containing 
fractions 
 
Figure 19: NP-TLC after CC of the triglycoside enriched 
fraction. Mobile phase: EtOAc:acetone:H2O ∼ 5:3:1; 6 
developments; detection at 366 nm after derivatisation 
with Natursoffreagenz A. CC according to 2.2.6.2 
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Overall, both isolation sequences results in chromatograms which do not show baseline 
separation of the compounds. Nevertheless, the methods are a relatively affordable and fast 
way to get the flavonoids in sufficient amounts for the following projects. In addition, the 
intermediate fractions which comprises two or more glycosides can be combined and added 
to the extract. Thereby, unnecessary loss of substance is avoided.  
Finally the following eight flavonoid glycosides were isolated.  
Isolated diglycosides:  
 3-O-(2-O-(-D-Glucosyl-α-L-rhamnosyl)kaempferol (calculated yield for 3 g 
enriched extract: 170 mg, 5.7%)  
 3-O-(6-O-(α-L-Rhamnosyl)--D-glucosyl)kaempferol (calculated yield for 3 g 
enriched extract: 230 mg, 7.7%)  
 3-O-(6-O-(α-L-Rhamnosyl)--D-glucosyl)isorhamnetin 
 3-O-(6-O-(α-L-Rhamnosyl)--D-glucosyl)quercetin 
 3-O-(6-O-(α-L-rhamnosyl)--D-glucosyl)myricetin 
 
Isolated triglycosides: 
 3-O-(2-O, 6-O-Bis(α-L-rhamnosyl)--D-glucosyl)kaempferol (calculated yield for 5 
g enriched extract: 65 mg, 1.3%)  
 3-O-(2-O, 6-O-Bis(α-L-rhamnosyl)--D-glucosyl)isorhamnetin 
 3-O-(2-O, 6-O-Bis(α-L-rhamnosyl)--D-glucosyl)quercetin 
The yields for the myricetin-, quercetin- and isorhamnetin glycosides are not presented, 
because the chromatographic separation was not focused on their isolation and thus, the 
calculated contents would not be informative. 
The identification of the kaempferol glycosides was achieved by comparison with 1H NMR 
literature values52 (Table 1-Table 8) and the further down presented analysis by HPLC-MS 
(Figure 21) . 
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Position 
1
H 
1
HLIT 
6 6.21 (1H, d, 2.0) 6.20 (1H, d, 2.0) 
8 6.39 (1H, d, 2.0) 6.39 (1H, d, 2.0) 
2´,6´ 7.28 (2H, s) 7.29 (2H, s) 
1´´ 5.08 (1H, d, 7.7) 5.08 (1H, d, 7.6) 
6´´A 3.80 (1H, d, 10.5) 3.80 (1H, d, 10.7) 
1´´´ 4.52 (1H, d, 1.3) 4.52 (1H, d, 1.2) 
2´´´ 3.62 (1H, dd, 1.5, 3.3) 3.62 (1H, dd, 1.2, 3.5) 
3´´´ 3.55 (1H, dd, 3.3, 9.3) 3.55 (1H, dd, 3.5, 9.4) 
6´´´ 1.12 (3H, d, 6.2) 1.12 (3H, d, 6.2) 
Remaining 
sugar 
protons 
3.51-3.23 (7H, m) 3.50-3.25 (7H, m) 
 
Table 1: 
1
H NMR spectral data of 3-O-(6-O-(α-L-rhamnosyl)--D-
glucosyl)myricetin (300 MHz, 294 K,  J in Hz, in CD3OD) compared 
to literature values
52
 
Position 
1
H 
1
HLIT 
6 6.21 (1H, d, 2.1) 6.19 (1H, d, 2.1) 
8 6.40 (1H, d, 2.1) 6.37 (1H, d, 2.1) 
2´ 7.66 (1H, d, 2.1) 7.67 (1H, d, 2.2) 
5´ 6.87 (1H, d, 8.4) 6.87 (1H, d, 8.4) 
6´ 7.63 (1H, dd, 2.2, 8.4) 7.63 (1H, dd, 2.2, 8.4) 
1´´ 5.10 (1H, d, 7.5) 5.09 (1H, d, 7.2) 
6´´A 3.80 (1H, d, 10.9) 3.81 (1H, d, 10.0) 
1´´´ 4.51 (1H, s) 4.53 (1H, br s) 
2´´´ 3.62 (1H, dd, 1.4, 3.4) 3.65 (1H, m) 
3´´´ 3.53 (1H, dd, 3.6, 9.4) 3.55 (1H, dd, 3.1, 9.4) 
6´´´ 1.12 (3H, d, 6.2) 1.13 (3H, d, 6.1) 
Remaining 
sugar 
protons 
3.50-3.33 (7H, m) 3.82-3.25 (7H, m) 
 
Table 2: 
1
H NMR spectral data of 3-O-(6-O-(α-L-rhamnosyl)--D-
glucosyl)quercetin (300 MHz, 295 K, J in Hz, in CD3OD) compared 
to literature values
52
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Position 
1
H 
1
HLIT 
6 6.21 (1H, d, 2.1) 6.19 (1H, d, 1.9) 
8 6.40 (1H, d, 2.1) 6.38 (1H, d, 1.9) 
2´,6´ 8.06 (2H, d, 8.9) 8.06 (2H, d, 8.9) 
3´,5´ 6.89 (2H, d, 8.9) 6.88 (2H, d, 8.9) 
1´´ 5.13 (1H, d, 7.5) 5.12 (1H, d, 7.6) 
6´´A 3.80 (1H, dd, 1.9, 7.6) 3.81 (1H, d, 10.6) 
1´´´ 4.51 (1H, d, 1.4) 4.52 (1H, d, n.r.) 
2´´´ 3.63 (1H, dd, 1.6, 3.3) 3.64 (1H, m) 
3´´´ 3.52 (1H, dd, 3.4, 9.5) 3.53 (1H, dd, 3.3, 9.4) 
6´´´ 1.12 (3H, d, 6.2) 1.13 (3H, d, 6.2) 
Remaining 
sugar 
protons 
3.48-3.23 (7H, m) 3.48-3.25 (7H, m) 
 
Table 4: 
1
H NMR spectral data of 3-O-(6-O-(α-L-rhamnosyl)--D-
glucosyl) kaempferol (300 MHz, 294 K, J in Hz, in CD3OD) compared 
to literature values;
52
 n.r.: not reported 
Position 
1
H 
1
HLIT 
6 6.20 (1H, d, 2.1) 6.19 (1H, d, 2.1) 
8 6.40 (1H, d, 2.1) 6.37 (1H, d, 2.1) 
2´ 7.94 (1H, d, 2.0) 7.94 (1H, d, 2.1) 
3´-O-CH3 3.94 (3H, s) 3.95 (3H,s) 
5´ 6.91 (1H, d, 8.5) 6.91 (1H, d, 8.5) 
6´ 7.62 (1H, dd, 2.1, 8.4) 7.59 (1H, dd, 2.1, 8.5) 
1´´ 5.23 (1H, d, 7.4) 5.22 (1H, d, 7.6) 
6´´A 3.81 (1H, d, 10.2) 3.81 (1H, d, 10.6) 
1´´´ 4.52 (1H, d, 1.3) 4.54 (1H, d, n.r.) 
2´´´ 3.61 (1H, dd, 1.6, 3.3) 3.63 (1H, d, 3.4) 
6´´´ 1.09 (3H, d, 6.2) 1.11 (3H, d, 7.6) 
Remaining 
sugar 
protons 
3.51-3.20 (7H, m) 3.51-3.24 (7H, m) 
 
Table 3: 
1
H NMR spectral data of 3-O-(6-O-(α-L-rhamnosyl)--D-
glucosyl)isorhamnetin (300 MHz, 297 K, J in Hz, in CD3OD) compared 
to literature values
52
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Position 
1
H 
1
HLIT 
6 6.20 (1H, d, 1.9) 6.20 (1H, d, 1.9) 
8 6.37 (1H, d, 2.1) 6.37 (1H, d, 1.9) 
2´,6´ 7.77 (2H, d, 8.8) 7.76 (2H, d, 8.9) 
3´,5´ 6.94 (2H, d, 8.8) 6.94 (2H, d, 8.9) 
1´´ 5.72 (1H, d, 1.4) 5.73 (1H, d, 1.1) 
2´´ 4.28 (1H, dd, 1.5, 3.5) 4.29 (1H, dd, 1.3, 3.5) 
3´´ 3.80 (1H, dd, 3.5, 9.4) 3.81 (1H, dd, 3.5, 9.3) 
6´´ 0.93 (3H, d, 5.9) 0.94 (3H, d, 5.9) 
1´´´ 4.41 (1H, d, 7.7) 4.42 (1H, d, 7.7) 
6´´´ 3.73-3.65 (2H, m) 3.70 (2H,m) 
Remaining 
sugar 
protons 
3.44-3.17 (6H, m) 3.43-3.19 (6H, m) 
 
Table 5: 
1
H NMR spectral data of 3-O-(2-O-(-D-glucosyl-α-L-
rhamnosyl)kaempferol (300 MHz, 297 K, J in Hz, in CD3OD) 
compared to literature values
52
 
Position 
1
H 
1
HLIT 
6 6.18 (1H, d, br s) 6.18 (1H, d, 2.0) 
8 6.36 (1H, br s) 6.37 (1H, d, 2.0) 
2´ 7.59 (1H, br s) 7.59 (1H, br s) 
5´ 6.87 (1H, d, 8.4) 6.87 (1H, d, 8.8) 
6´ 7.62 (1H, d, 1.9) 7.61 (1H, dd, 2.1, n.r) 
1´´ 5.59 (1H, d, 7.6) 5.59 (1H, d, 7.6) 
1´´´ 5.22 (1H, br s) 5.22 (1H, d, 1.3) 
2´´´ 4.00 (1H, dd, 1.7, 2.8) 4.01 (1H, dd, 1.5, 3.3) 
5´´´ 4.08 (1H, dd, 6.2, 9.6) 4.09 (1H, dd, 6.2, 9.6) 
6´´´ 1.00 (3H, d, 6.2) 1.00 (3H, d, 6.2) 
1´´´´ 4.50 (1H, br s) 4.51 (1H, d,1.5) 
6´´´´ 1.07 (3H, d, 6.2) 1.09 (3H, d, 6.2) 
Remaining 
sugar 
protons 
3.90-3.18 (12H, m) 4.07-3.21 (12H, m) 
 
Table 6: 
1
H NMR spectral data of 3-O-(2-O, 6-O-bis(α-L-
rhamnosyl)--D-glucosyl)quercetin (300 MHz, 297 K, J in Hz, in 
CD3OD) compared to literature values;
52
 n.r.: not reported 
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Position 
1
H 
1
HLIT 
6 6.18 (1H, d, 2.1) 6.18 (1H, d, 2.0) 
8 6.38 (1H, d, 2.1) 6.39 (1H, d, 2.0) 
2´ 7.94 (1H, d,2.0) 7.94 (1H, d,1.9) 
3´-O-CH3 3.97 (3H,s) 3.97 (3H,s) 
5´ 6.91 (1H, d, 8.5) 6.92 (1H, d, 8.5) 
6´ 7.57 (1H, dd, 2.0, 8.5) 7.57 (1H, dd,1.9, 8.5) 
1´´ 5.73 (1H, d, 7.4) 5.74 (1H, d, 7.3) 
6´´A 3.81 (1H, d, 10.3) 3.81 (1H, d, 10.3) 
1´´´ 5.19 (1H, d, 1.2) 5.19 (1H, d, n.r.) 
2´´´ 4.00 (1H, dd, 1.6, 3.4) 4.00 (1H, dd, n.r) 
3´´´ 3.77 (1H, dd, 3.3, 9.5) 3.73 (1H, dd, 3.4, 9.6) 
5´´´ 4.06 (1H, dd, 6.3, 9.7) 4.04 (1H, dd, 6.3, 9.7) 
6´´´ 0.91 (3H, d, 6.2) 0.92 (3H, d, 6.2) 
1´´´´ 4.53 (1H, d, 1.4) 4.54 (1H, d, n.r.) 
6´´´ 1.06 (3H, d, 6.2) 1.07 (3H, d, 6.2) 
Remaining 
sugar 
protons 
3.89-3.17 (10H, m) 4.07-3.19 (10H, m) 
 
Table 7: 
1
H NMR spectral data of 3-O-(2-O, 6-O-bis(α-L-rhamnosyl)--
D-glucosyl)isorhamnetin (300 MHz, 297 K, J in Hz, in CD3OD) compared 
to literature values;
52
 n.r.: not reported 
Position 
1
H 
1
HLIT 
6 6.18 (1H, d, 2.1) 6.20 (1H, d, 2.0) 
8 6.38 (1H, d, 2.1) 6.40 (1H, d, 1.9) 
2´, 6´ 8.01 (2H, d, 8.9) 8.05 (2H, d, 8.9) 
3´, 5´ 6.89 (2H, d, 8.9) 6.92 (2H, d, 8.9) 
1´´ 5.60 (1H, d, 7.3) 5.63 (1H, d, 7.2) 
1´´´ 5.22 (1H, d, 1.2.) 5.25 (1H, d, n.r.) 
2´´´ 4.00 (1H, dd, 1.6, 3.3j) 4.02 (1H, m) 
5´´´ 4.06 (1H, dd, 6.2, 9.6) 4.08 (1H, dd, 6.3, 9.6) 
6´´´ 0.97 (3H, d, 6.2) 0.99 (3H, d, 6.2) 
1´´´´ 4.49 (1H, d, 1.4) 4.52 (1H, d, n.r.) 
6´´´´ 1.07 (3H, d, 6.2) 1.08 (3H, d, 6.2) 
Remaining 
sugar 
protons 
3.88-3.19 (12H, m) 3.85-3.22 (12H, m) 
 
Table 8: 
1
H NMR spectral data of 3-O-(2-O, 6-O-bis(α-L-rhamnosyl)-
-D-glucosyl)kaempferol (300 MHz, 297 K, J in Hz, in CD3OD) 
compared to literature values;
52
 n.r.: not reported 
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Extract Quantification 
The isolated kaempferol glycosides and an additional acylated kaempferol glycoside, which 
was a kind gift from Dr. Willmar Schwabe GmbH und Co. KG., were used in the next step for 
their quantification in the standardized extract EGb 761®. The following list contains these 
four compounds and their used abbreviations: 
 3-O-(2-O, 6-O-Bis(α-L-rhamnosyl)--D-glucosyl)kaempferol (Triglycoside) 
 3-O-(6-O-(α-L-Rhamnosyl)--D-glucosyl)kaempferol (Rutinoside) 
 3-O-(2-O-(-D-Glucosyl-α-L-rhamnosyl)kaempferol (Biloside) 
 3-O-(2-O-(6-O-(p-Hydroxy-trans-cinnamoyl)--D-glucosyl)-α-L-
rhamnosyl)kaempferol (Acylated Biloside) 
At first, the questions arises whether these four kaempferol glycosides are those with the 
highest content in EGb 761®. The extract was therefore analyzed by HPLC followed and high 
resolution mass spectrometry (Figure 21). The isolated kaempferol glycosides can clearly be 
assigned in the chromatogram of EGb 761® by comparison of the retention times and MS 
data with the pure reference compounds. Further on several other flavonoid glycosides and 
two ginkgolides can be assigned based on HR m/z values, which is consequently not an 
absolute evidence. The retention time of the two kaempferol monoglycosides cannot be 
associated to a certain peak in the chromatogram, because of similar molecular masses of 
the following substances: 
 Kaempferol-3-O--D-glucoside (448), luteolin-3´-O--D-glucoside, quercetin-3-O-α-L 
rhamnoside 
 Kaempferol-3-O- α-L-rhamnoside (432), apigenin-7-O--D-glucoside 
All conceivable signals for the monoglycosides have multiple smaller integrals compared to 
the four isolated compounds. Consequently, these substances can be regarded as the 
predominat kaempferol glycosides in EGb 761®. 
The chosen chromatographic method gives a good separation of the ingredients, which is 
sufficient for the quantification, although for instance the acylated biloside shows a little 
shoulder in the chromatogram (Figure 22) 
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Figure 21: Combination of HPLC (350 nm) and high resolution mass spectrometry (ESI) analysis of EGb 761® and 
tentative assignment of other compounds based on MS data. CC according to 2.2.7.2, but with formic acid instead of 
trifluoracetic acid 
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Figure 22: HPLC of EGb 761® at 350 nm. CC according to 2.2.7.2 
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In the following step the calibration curves for the four kaempferol glycosides were 
determinated (R2 = 0.9965-0.9993) and particular contents in EGb 761® were calculated as 
values between 1.58 and 2.17 % w/w (Table 9) 
 
 
 
 
 
 
Further on, to exclude any loss during the indispensable filtration step before the HPLC 
analysis, the integrals of the flavonoid signals were calculated for different extract 
concentrations. It could be shown, that the signal areas are linear to the used extract 
concentrations (Figure 23) which is a proof for the good solubility of the substances in the 
prepared HPLC samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Chromatographic 
purity of reference 
Content in  
EGb 761® [% w/w] 
Interday precision        
(n = 6) 
Intraday precision 
(n = 6) 
Triglycoside 98.1% 1.58 ± 0.02% 3.24% 1.84% 
Rutinoside 98.6% 2.17 ± 0.01% 2.09% 1.10% 
Biloside 100.0% 0.89 ± 0.01% 2.12% 1.84% 
Acyl. Biloside 95.4% 1.59 ± 0.01% 1.02% 1.26% 
 
Table 9: Content of four kaempferol glycosides in EGb 761®; the chromatographic purity of the references was considered 
for the calculation 
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Figure 23: Linearity of the calibration curves of the four kaempferol glycosides using different extract 
concentrations. CC according to 2.2.7.2 
R² = 0.9990-0.9994 
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3 Synthesis of five expected Kaempferol Metabolites 
3.1 Introduction: Synthetic Approach towards Flavonoid Glucuronides 
The flavonol kaempferol can be conjugated in vivo within phase-II-metabolism with a sulfate 
moiety or a glucuronic acid (for more details see page 
84). The substitution takes place at the hydroxyl 
functions of the molecule. Although the reaction is 
catalyzed in vivo by an enzyme, it should be noted 
that not all four hydroxyl groups have the same 
reactivity. For instance, regarding published sulfation 
or methylation reactions, the proton with the highest 
acidity and consequently the highest reactivity seems to be at 7-OH.53,54 This could be partly 
based on the fact that the corresponding alkoxide is resonance stablized by the 4-pyrone 
carbonyl group. The proton at 5-OH has, as expected, the lowest reactivity, due to the 
hydrogen bond to the 4-pyrone carbonyl. Based on this information, some possible 
metabolites of kaempferol should be synthesized in the laboratory to confirm their presence 
or absence in rat plasma in the following in vivo tests. 
 
 
 
 
 
 
 
 
 
 
 
Figure 24: The flavonol kaempferol 
Figure 25: Possible phase-II-metabolites of  kaempferol in rat plasma 
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In general the following reaction conditions, which are briefly summarized here, are 
conceivable for the formation of the glycosidic bond. The literature suggest different 
methods for the synthesis of flavonoid glycosides: 
For the generation of glucuronides: 
 Ag2O, CaSO4, pyridine (quinoline
55), 1-bromo-2,3,4-tri-O-acetyl-α-D-glucuronic 
acid methyl ester, RT, 2 h, 45% yield56 
 BF3*Et2O, 3 Å molecular sieve, DCM, 2,3,4-tri-O-acetyl-α-D-glucuronic acid methyl 
ester trichloroacetimidate, -15 °C, over night, 58% yield57 
 K2CO3, DMF, 1-bromo-2,3,4,6-tetra-O-acetyl-α-D-glucopyranoside, RT, 12 h, 54% 
yield54,58 
For the generation of glucosides: 
 Saturated aqueous KHCO3, TDA (tris(3,6-dioxaheptyl)amine, phase transfer 
catalyst), DCM, 1-bromo-2,3,4,6-tetra-O-acetyl-α-D-glucopyranoside, 40 °C, 48 h, 
30% yield59 
 Aqueous K2CO3, TBAB (tetra-n-butylammonium bromide, phase transfer catalyst), 
CHCl3, 1-bromo-3,6-Di-O-acetyl-2,4-di-O-benzyl-α-D-glucopyranoside, 50 °C, 8 h, 
54% yield60 
Usually, also the synthesis of a kaempferol glucoside followed by a TEMPO (2,2,6,6-
tetramethylpiperidinyloxyl) oxidation, which is known to be selective for primary alcohols, 
would yield in the formation of the desired kaempferol glucuronides. Nevertheless, with 
regard to the additional synthetic step, direct glucuronidation is favoured. Furthermore, 
there is no evidence why the shown reaction condition for the generation of glucosides 
could not be accomplished with the glucuronic acid, instead. 
The bromo derivate of the glucuronic acid is about 18 fold cheaper compared to the 
trichloroacetimidate.61 Further on, the published yields do not differ in a large scale from 
each other and consequently a modified Koenigs-Knorr reaction seemed to be the right 
choice to start with. 
  
 Synthesis of five expected Kaempferol Metabolites 
~ 45 ~ 
  
3.2 Material and Methods 
3.2.1 Consumable Material 
3.2.1.1 Solvents 
 Acetone, EMSURE®, Merck KGaA, Darmstadt, Germany 
 Methanol, ≥ 99% (GC), Merck KGaA, Darmstadt, Germany 
 Tetrahydrofuran, dried, Merck KGaA, Darmstadt, Germany 
 H2O, deionised, further purified by membraPure, Astacus, MembraPure GmbH, 
Berlin, Germany 
 Pyridine, ≥ 99.5%, Merck KGaA, Darmstadt, Germany 
 N,N-Dimethylformamide (H2O ≤ 0.01%), ≥ 99.8% (GC), Sigma-Aldrich, Steinheim, 
Germany 
 Acetonitrile, LiChrosolv®, ≥ 99.9%, Merck KGaA, Darmstadt, Germany 
 Ethanol, ≥ 99.9%, J.T.Baker®, Avantor Performance Materials, Center Valley, PA, 
USA 
3.2.1.2 TLC 
 TLC Silica gel 60 RP-18 F254S, Merck KGaA, 64271 Darmstadt, Germany 
 TLC chambers, Camag, Muttenz, Switzerland 
 UV-viewing cabinet, Camag, Muttenz, Switzerland 
3.2.1.3 NMR 
 Acetone-d6, 99.8%, Deutero GmbH, 56288 Kastellaun, Germany 
 Bruker Avance 300, Bruker Corporation, Billerica, USA 
 Chloroform–d, 99.8%, Sigma-Aldrich, Steinheim, Germany 
 Dimethylsulfoxid-d6, 99.8%, Deutero GmbH, Kastellaun, Germany 
 Methanol-d4, 99.8%, Deutero GmbH, 56288 Kastellaun, Germany 
 NMR tubes, 507-HP, 203 mm, Norell, Landisville, USA 
3.2.1.4 Chemicals 
 Amano Lipase PS, from Burkholderia cepacia, ≥ 30000 U/g, Sigma-Aldrich, 
Steinheim, Germany 
 Benzyl bromide, ≥ 98%(GC), Merck Schuchardt OHG, Hohenbrunn, Germany 
 Calcium sulfate, -325 mesh, 99%, Sigma-Aldrich, Steinheim, Germany 
 Cyclohexene, ≥ 99% (GC), Merck Schuchardt OHG, Hohenbrunn, Germany 
 Dowex 50 W X 4, H+-form, 20-50 mesh, Fluka, Neu-Ulm, Germany 
 Kaempferol, ≥ 90%, Lyon, France 
 N,N'-Dicyclohexylcarbodiimide, 99%, Alfa Aesar, Heysham, England 
 Palladium hydroxide, 20 wt.% Pd (Dry Basis) on carbon, moist, Sigma-Aldrich, 
Steinheim, Germany 
 Potassium acetate extra pure, Merck KGaA, Darmstadt, Germany 
 Synthesis of five expected Kaempferol Metabolites 
~ 46 ~ 
  
 Potassium carbonate, Honeywell Riedel-de Haën, Seelze, Germany 
 Silver(I) oxide, 99+% (metal basis) Powder, Alfa Aesar GmbH & Co KG, Karlsruhe, 
Germany 
 Sodium hydrogen carbonate, Merck KGaA, Darmstadt, Germany 
 Tetrabutylammonium hydrogen sulfate, pure, AppliChem, Darmstadt, Germany 
 Trifluoroacetic acid, 99%, Sigma-Aldrich, Steinheim, Germany 
 Celite® 560, particle size ≤ 148.5 µm, 56%, Sigma-Aldrich, Steinheim, Germany 
 Acetic anhydride, ≥ 98.5%, Merck KGaA, Darmstadt, Germany 
 Potassium chloride, ≥ 99.5%, Merck KGaA, Darmstadt, Germany 
 Sodium carbonate, anhydrous, ≥ 99.5%, Merck KGaA, Darmstadt, Germany 
 Acetic acid, ≥ 99.8%, Merck KGaA, Darmstadt, Germany 
 1-Bromo-2,3,4-tri-O-acetyl-α-D-glucuronic acid methyl ester, > 95%, ReseaChem 
GmbH, Burgdorf, Switzerland 
3.2.2 Columns 
 Flash-RP: SuperVarioPrep® D40, 46 x 186 mm, filled with stationary phase RP18 
25-40 µm, 90 g, Merck KGaA, 64271 Darmstadt, Germany 
 Semipreparative HPLC: Knauer, Vertex, 16 x 250 mm, filled with stationary phase 
Eurospher-100 C18-7 µm, Dr. Ing. Herbert Knauer GmbH, Berlin, Germany 
3.2.3 Instruments 
 1D NMR: Avance 300, Bruker, Billerica, USA 
 1D NMR: Avance 400, Bruker, Billerica, USA 
 2D NMR: Avance III 600, Bruker, Billerica, USA 
 Flash-RP: SuperVarioPrep® D40, 46 x 186 mm, filled with stationary phase RP18 
25-40 µm, 90 g, Merck KGaA, 64271 Darmstadt, Germany 
 Mass spectrometer: 
 TOF 6540 UHD, Agilent, Santa Clara, USA 
 Electrospray ionization (ESI) 
 Semipreparative HPLC: Knauer, Vertex, 16 x 250 mm, filled with stationary phase 
Eurospher-100 C18-7 µm, 14163 Berlin, Germany 
 UV-Visible Spectrophotometer, 50 Scan, Varian, Agilent, Santa Clara, USA 
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3.3 Chemistry and Analytical Data 
3.3.1 Synthesis of Kaempferol-4´-O--D-glucuronide 
3.3.1.1 Synthesis of 3,7-Di-O-benzyl-kaempferol 
 
Kaempferol (350.0 mg, 1.22 mmol) and dry potassium carbonate (997.0 mg, 7.21 mmol, 
5.9 eq) were suspended in 12.2 mL DMF and 291 µL benzyl bromide (2.45 mmol, 2.0 eq) 
were added. After stirring in the dark for 2 h and under nitrogen atmosphere the reaction 
mixture was filtrated and the solvent was removed under nitrogen stream. The crude 
product was purified by flash column chromatography using a H2O/acetonitrile gradient.
62,58 
Chromatographic parameter: 
Instrument:  Flash chromatography 
Column:  Merck, SuperVarioPrep® D40, 46 x 186 mm 
Stationary phase: Merck, RP18 25-40 µm, 90 g, 40 x 115 mm 
Mobile phase:  A: H2O, B: acetonitrile 
Application:  Suspension in 80% aqueous acetonitrile 
Fractionation:  33 min 
Gradient:  0 min: 80% acetonitrile 
   15 min: 95% acetonitrile 
   25-33 min: 100% MeOH 
Flow:   45 mL/min 
Region of Retention: 6–15 min, 270–675 mL 
File:   120125-1016-1 
 50 fractions each 30 mL 
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Position 
1
H 
6 6.45 (1H, d, 2.2) 
8 6.51 (1H, d, 2.2) 
2´,6´ 7.94 (2H, d, 8.8) 
3´,5´ 6.89 (2H, d, 8.8) 
O-CH2 5.13 (2H, s) 
O-CH2 5.06(2H, s) 
Ph-protons 7.44-7.27 (10H, m) 
OH 12.71 (1H, s) 
 
Table 10: 
1
H NMR spectral data of 3,7-di-O-benzyl-
kaempferol (300 MHz, 295 K, J in Hz, in CDCl3) 
State of aggregation Yellow solid 
Amount [mg] 200 
Yield [%] 35 
m/z [M+H]
+
 467.1492 
Calc m/z [M+H]
+
 467.1489 
 
Table 11:Data of 3,7-di-O-benzyl-kaempferol 
Figure 26: Structure of 3,7-di-O-benzyl-kaempferol 
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3.3.1.2 Synthesis of 3,7-Di-O-benzyl-kaempferol-4’-O-(2‘‘, 3‘‘, 4‘‘-tri-O-acetyl)--D-
glucuronic acid methyl ester 
 
3,7-Di-O-benzyl-kaempferol (200.0 mg, 429.2 µmol), calcium sulfate (470.0 mg) and silver-
(I)oxide (248.6 mg, 1.07 mmol, 2.5 eq) were suspended in 5.6 mL acetonitrile at 0 °C. 
Afterwards, 1-bromo-2,3,4-tri-O-acetyl-α-D-glucuronic acid methyl ester (210.0 mg, 536.5 
µmol, 1.25 eq) and 925 µL pyridine were added. After 15 minutes, the ice bath was removed. 
The reaction mixture was stirred at room temperature for 3.5 h and then filtered. The crude 
product was purified within two steps by flash column chromatography followed by 
semipreparative HPLC using a H2O/acetonitrile-gradient each time. 
1. Chromatographic parameter: 
Instrument:  Flash chromatography 
Column:  Merck, EasyVarioPrep®, 30 x 142 mm, self packed 
Stationary phase: Merck, LiChroprep® RP-18, 25-40 µm, ~35 g, 25 x 110 mm  
   + 5 g precolumn 
Mobile phase:  A: H2O, B: acetonitrile 
Application:  527 mg crude product + 700 mg RP18 
Fractionation:  25 min 
Gradient:  0 min: 85% acetonitrile 
   20 min: 95% acetonitrile 
   20-25 min: 100% acetonitrile 
Flow:   25 mL/min 
File:   120306-0924-1 
Region of Retention: 4-6.5 min, 100-160 mL 
 31 fractions each 20 mL 
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2. Chromatographic parameter: 
Instrument:  Semipreparative HPLC 
Column:  Knauer, Vertex, 16 x 250 mm 
Stationary phase: Eurospher-100 C18-7 µm 
Mobile phase:  A: H2O, B: acetonitrile 
Application:  Liquid injection in 95% aqueous acetonitrile 
Fractionation:  12 min 
Gradient:  0 min: 85% acetonitrile 
   10 min: 95% acetonitrile 
   10-11 min: 95% acetonitrile 
   12 min: 85% acetonitrile 
Flow:   10 mL/min 
Retention time (tR): 7.3 min 
λmax [nm] at tR: 221, 266, 345 
File:   2012-03/158-160 
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Position 
1
H 
6 6.47 (1H, d, 2.0) 
8 6.82 (1H, d, 1.9) 
2´,6´ 7.97 (2H, d, 9.0) 
3´,5´ 7.13 (2H, d, 9.0) 
1´´ 5.79 (1H, d, 7.9) 
Sugar proton 5.48 (1H, t, 9.0) 
Sugar protons 5.04-5.18 (2H, m) 
Sugar proton 4.72 (1H, t, 9.9) 
O-CH3 3.62 (3H, s) 
CO-CH3 2.00 (3H, s) 
CO-CH3 2.01 (3H, s) 
CO-CH3 1.99 (3H, s) 
O-CH2 5.21 (2H, s) 
O-CH2 5.03 (2H, s) 
Ph-protons 7.48-7.30 (10H, m) 
 
Table 12: 
1
H NMR spectral data of 3,7-di-O-
benzyl-kaempferol-4´-O-(2‘‘,3‘‘,4‘‘-tri-O-
acetyl)--D-glucuronic acid methyl ester            
(300 MHz, 295 K, J in Hz, in DMSO-d6) 
State of aggregation Pale yellow solid 
Amount [mg] 77 
Yield [%] 18 
m/z [M+H]
+
 783.2287 
Calc m/z [M+H]
+
 783.2283 
 
Table 13: Data of 3,7-di-O-benzyl-kaempferol-4´-O-
(2‘‘,3‘‘,4‘‘-tri-O-acetyl)--D-glucuronic acid methyl ester 
Figure 27: Structure of 3,7-di-O-benzyl-kaempferol-4´-O-
(2‘‘,3‘‘,4‘‘-tri-O-acetyl)--D-glucuronic acid methyl ester 
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3.3.1.3 Synthesis of Kaempferol-4’-O-(2‘‘, 3‘‘, 4‘‘-tri-O-acetyl)--D-glucuronic acid 
methyl ester 
 
3,7-Di-O-benzyl-kaempferol-4´-O-(2‘‘,3‘‘,4‘‘-tri-O-acetyl)--D-glucuronic acid methyl ester 
(53.6 mg, 68.5 µmol) was suspended in 8 mL ethanol and 2 mL cyclohexene (CyHe). 
Afterwards, Pd(OH)2 on charcoal (12.0 mg) was added. The mixture was stirred under 
nitrogen atmosphere and reflux for 45 min.57 After cooling the suspension was filtrated and 
the solvent was evaporated under nitrogen stream. The product was used without any 
further purification in the next step. 
 
 
 
 
 
 
 
 
 
 
 
 
 
State of aggregation Pale yellow solid 
Amount [mg] 36.4 
Yield [%] 88 
m/z [M-H]
-
 601.1198 
Calc m/z [M-H]
-
 601.1199 
 
Table 15: Data of kaempferol-4’-O-(2‘‘,3‘‘,4‘‘-tri-O-acetyl)--D-
glucuronic acid methyl ester 
Position 
1
H 
6 6.31 (1H, d, 2.0) 
8 6.61 (1H, d, 2.1) 
2´,6´ 8.28 (2H, d, 9.1) 
3´,5´ 7.38 (2H, d, 9.0) 
1´´ 6.06 (1H, d, 3.6) 
Sugar proton 5.73 (1H, t, 9.8) 
Sugar proton 5.26 (1H, t, 9.7) 
Sugar proton 5.18 (1H, dd, 3.6, 10.1) 
Sugar proton 4.48 (1H, t, 10.0) 
O-CH3 3.68 (3H, s) 
CO-CH3 2.05 (3H, s) 
CO-CH3 2.04 (3H, s) 
CO-CH3 2.01 (3H, s) 
 
Table 14: 
1
H NMR spectral data of kaempferol-4´-O-
(2‘‘,3‘‘,4‘‘-tri-O-acetyl)--D-glucuronic acid methyl 
ester, (300 MHz, 295 K, J in Hz, in acetone-d6) 
 
Figure 28: Structure of kaempferol-4’-O-(2‘‘,3‘‘,4‘‘-tri-O-acetyl)--
D-glucuronic acid methyl ester 
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3.3.1.4 Synthesis of Kaempferol-4’-O--D-glucuronide 
 
Kaempferol-4’-O-(2‘‘,3‘‘,4‘‘-tri-O-acetyl)--D-glucuronic acid methyl ester (36.4 mg, 
60.4 µmol) was dissolved in 20 mL 50% aq. MeOH. After addition of 0.6 mL aq. sodium 
carbonate (0.5 M), the reaction mixture was stirred at room temperature for 90 min. After 
cooling the pH was ajusted ≤ 3 with Dowex 50 W X 4 resin. The mixture was filtrated and the 
residue was washed with 20 mL 50% aq. MeOH and 20 mL MeOH. The crude product was 
purified by semipreparative HPLC. 
Chromatographic parameter: 
Instrument:  Semipreparative HPLC 
Column:  Knauer, Vertex, 16 x 250 mm 
Stationary phase: Eurospher-100 C18-7 µm 
Mobile phase:  A: H2O+0.1% TFA, B: acetonitrile+0.1% TFA 
Application:  Liquid injection in 15% aqueous acetonitrile 
Fractionation:  19 min 
Gradient:  0 min: 10% acetonitrile+0.1% TFA 
   35 min: 35% acetonitrile+0.1% TFA 
   35-40 min: 35% acetonitrile+0.1% TFA 
   45 min: 10% acetonitrile+0.1% TFA 
Flow:   10 mL/min 
Retention Time (tR): 30.0 min 
λmax [nm] at tR: 221, 264, 318, 362 
File:   2012-03/178-179 
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Position 
1
H 
13
C 
2  146.3 
3  136.5 
4  176.3 
5  160.8 
6 6.19 (1H, d, 2.1) 98.5 
7  164.1 
8 6.46 (1H, d, 2.1) 93.9 
9  156.6 
10  103.4 
2´,6´ 8.10 (2H, d, 9.1) 129.6 
3´,5´ 7.17 (2H, d, 9.1) 116.4 
1´´ 5.16 (1H, d, 7.5) 99.7 
2´´ 3.32-3.28 (1H, m) 73.0 
3´´ 3.36-3.32 (1H, m) 75.8 
4´´ 3.40 (1H, t, 9.2) 71.5 
5´´ 3.95 (1H, d, 9.7) 75.6 
6´´  170.3 
 
Table 16: 
1
H and 
13
C NMR spectral data of kaempferol-4´-O-
-D-glucuronide (600/150 MHz, 298 K, J in Hz, in DMSO-d6) 
Figure 29: Structure of kaempferol-4´-O--D-
glucuronide 
State of aggregation yellow solid 
Amount [mg] 10.5 
Yield [%] 38 
m/z [M-H]
-
 461.0725 
Calc m/z [M-H]
-
 461.0725 
λmax in acetonitrile 
249.9, 267.0, 318.0, 
363.0 
Molar absorptivity (n=3) 
[L•mol-1•cm-1] 
10333 
(362.7 nm) 
 
Table 17: Data of kaempferol-4´-O--D-glucuronide 
 Synthesis of five expected Kaempferol Metabolites 
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3.3.2 Synthesis of Kaempferol-7-O--D-glucuronide and Kaempferol-7,4’-di-O--
D-glucuronide 
3.3.2.1 Synthesis of 3,5,7,4’-Tetra-O-acetyl-kaempferol 
 
Kaempferol (500 mg, 1.75 mmol) was dissolved in 4.95 mL acetic anhydride. After the 
addition of 524 µL pyridine, the reaction mixture was heated to reflux (145 °C) for 5 h. 
8.7 mL of ice-cold H2O were added and the precipitate was filtered off and washed with ice-
cold H2O. The crude product was used without further purification in the next step. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Position 
1
H 
6 7.03 (1H, d, 2.2) 
8 7.52 (1H, d, 2.2) 
2´,6´ 8.03 (2H, d, 8.8) 
3´,5´ 7.38 (2H, d, 8.8) 
4x CO-CH3 2.35 (3H, s) 
2.34 (3H, s) 
2.32 (3H, s) 
2.30 (3H, s) 
 
Table 18: 
1
H NMR spectral data of 3,5,7,4’-tetra-
O-acetyl-kaempferol (300 MHz, 298 K, J in Hz, in 
acetone-d6) 
State of aggregation white solid 
Amount [mg] 728 
Yield [%] 92% 
m/z [M+H]
+
 455.0973 
Calc m/z [M+H]
+
 455.0973 
 
Table 19: Data of 3,5,7,4’-tetra-O-acetyl-kaempferol 
Figure 30: Structure of 3,5,7,4’-tetra-O-acetyl-
kaempferol 
 Synthesis of five expected Kaempferol Metabolites 
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3.3.2.2 Synthesis of 3,5-Di-O-acetyl-kaempferol 
 
Peracetylated kaempferol (727.0 mg, 1.60 mmol) was dissolved in 87.5 mL dry THF. 1-
Butanol (801 µL, 8.75 mmol, ∼ 5 eq) and Burkholderia cepacia lipase (BCL, 1.75 g, 20 mg/mL) 
were added. The reaction mixture was stirred for 8 days at 42 °C. The lipase was filtered off 
and the solvent was evaporated under nitrogen stream. The crude product was purified by 
flash column chromatography. 
Chromatographic parameter: 
Instrument:  Flash chromatography 
Column:  Merck, SuperVarioPrep® D40, 46 x 186 mm 
Stationary Phase: Merck, RP18 25-40 µm, 90 g, 40 x 115 mm + 5 g precolumn 
Mobile Phase:  A: H2O, B: acetone 
Application:  Suspension in 30% aqueous acetone 
Fractionation:  35 min 
Gradient:  0 min: 20% acetone 
   20 min: 75% acetone 
   23 min: 100% acetone 
   35 min: 100% acetone 
Flow:   50 mL/min 
Region of Retention: 5.5-8.5 min, 275–425 mL 
File:   120307-1254-1 
  
 Synthesis of five expected Kaempferol Metabolites 
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Position 
1
H 
6 6.64 (1H, d, 2.3) 
8 6.95 (1H, d, 2.3) 
2´,6´ 7.83 (2H, d, 8.9) 
3´,5´ 7.03 (2H, d, 8.9) 
2x CO-CH3 2.30 (3H, s) 
2.28 (3H, s) 
 
Table 20: 
1
H NMR spectral data of 3,5-di-O-
acetyl-kaempferol (300 MHz, 298 K, J in Hz, 
in acetone-d6) 
State of aggregation white solid 
Amount [mg] 94.4 
Yield [%] 15 
m/z [M+H]
+
 371.0761 
Calc m/z [M+H]
+
 371.0762 
 
Table 21. Data of 3,5-di-O-acetyl-kaempferol 
Figure 31: Structure of 3,5-di-O-acetyl-
kaempferol 
 Synthesis of five expected Kaempferol Metabolites 
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3.3.2.3 One-Pot synthesis of 3,5-Di-O-acetyl-kaempferol-7-O-(2‘‘,3‘‘,4‘‘-tri-O-acetyl)-
-D-glucuronic acid methyl ester and 3,5-Di-O-acetyl-kaempferol-7,4’-O-di-
(2‘‘, 3‘‘, 4‘‘-tri-O-acetyl)--D-glucuronic acid methyl ester 
 
3,5-Di-O-acetyl-kaempferol (106.4 mg, 335.1 µmol), calcium sulfate (558.0 mg) and silver(I)-
oxide (163.1 mg, 707.8 µmol, 2.1 eq) were suspended in 4.5 mL acetonitrile. Afterwards 1-
bromo-2,3,4-tri-O-acetyl-α-D-glucuronic acid methyl ester (197.2 mg, 502.7 µmol, 1.5 eq) 
was added. After 2.5 and 3 h another 15 mg of the glucuronic acid were added. The reaction 
mixture was stirred overall for 4 h at room temperature. Subsequently, 22 mL aq. KCl (10%, 
w/w) and 112 mL aqueous acetic acid (10%, v/v) were added and the mixture was filtered 
through celite.57 The residue was washed with 100 mL H2O and the crude product was 
eluted with 100 mL acetone. The solvent was evaporated under nitrogen stream before the 
crude product was purified by semipreparative HPLC.  
Chromatographic parameter: 
Instrument:  Semipreparative HPLC 
Column:  Knauer, Vertex, 16 x 250 mm 
Stationary phase: Eurospher-100 C18-7 µm 
Mobile phase:  A: H2O, B: acetonitrile 
Application:  Liquid injection in 55% aqueous acetonitrile 
Fractionation:  17 min 
Gradient:  0 min: 45% acetonitrile 
   15 min: 70% acetonitrile 
   15-17 min: 70% acetonitrile 
   18 min: 45% acetonitrile 
 Synthesis of five expected Kaempferol Metabolites 
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Flow:   10 mL/min 
Retention time (tR): 7-Glucuronide    7,4´-Diglucuronide 
   11.0 min    15.5 min 
λmax [nm] at tR: 7-Glucuronide    7,4´-Diglucuronide  
209, 248, 324    222, 249, 307 
File:   2012-03/166-173 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Position 
1
H 
6 6.87 (1H, d, 2.4) 
8 7.33 (1H, d, 2.4) 
2´,6´ 7.84 (2H, d, 8.9) 
3´,5´ 7.04 (2H, d, 8.9) 
1´´ 5.87 (1H, d, 7.6) 
Sugar proton 5.50 (1H, t, 9.5) 
Sugar proton 5.30 (1H, dd, 7.6, 9.5) 
Sugar proton 5.26 (1H, t, 9.6) 
Sugar proton 4.71 (1H, d, 9.7) 
O-CH3 3.69 (3H, s) 
2x CO-CH3 
(aglycone) 
2.32 (3H, s) 
2.29 (3H, s) 
3x CO-CH3 
(sugar) 
2.04 (3H, s) 
2.02 (3H, s) 
2.01 (3H, s) 
 
Table 22: 
1
H NMR spectral data of 3,5-di-O-
acetyl-kaempferol-7-O-(2‘‘,3‘‘,4‘‘-tri-O-acetyl)-
-D-glucuronic acid methyl ester (400 MHz, 
298 K, J in Hz, in acetone-d6) 
State of aggregation pale yellow solid 
Amount [mg] 11.2 
Yield [%] 10 
m/z [M+H]
+
 687.1559 
Calc m/z [M+H]
+
 687.1556 
 
Table 23: Data of 3,5-di-O-acetyl-kaempferol-7-O-
(2‘‘,3‘‘,4‘‘-tri-O-acetyl)--D-glucuronic acid methyl ester 
Figure 32: Structure of 3,5-di-O-acetyl-kaempferol-7-O-
(2‘‘,3‘‘,4‘‘-tri-O-acetyl)--D-glucuronic acid methyl ester 
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Position 
1
H 
6 6.89 (1H, d, 2.4) 
8 7.34 (1H, d, 2.4) 
2´,6´ 7.93 (2H, d, 9.0) 
3´,5´ 7.28 (2H, d, 9.0) 
Anomeric 
protons 
5.87 (1H, d, 7.6) 
5.74 (1H, d, 7.8) 
Sugar protons 5.49 (2H, t, 9.5) 
Sugar protons 5.33-5.22 (4H, m) 
Sugar proton 4.71 (1H, d, 9.8) 
Sugar proton 4.67 (1H, d, 9.9) 
O-CH3 3.71 (3H, s) 
O-CH3 3.68 (3H, s) 
2x CO-CH3 
(aglycone) 
2.32 (3H, s) 
2.28 (3H, s) 
6x CO-CH3 
(sugar) 
2.04 (3H, s) 
2.03 (3H, s) 
2.02 (6H, s) 
2.014 (3H,s) 
2.013 (3H,s) 
 
Table 24: 
1
H NMR spectral data of 3,5-di-O-
acetyl-kaempferol-7,4´-di-O-(2‘‘, 3‘‘, 4‘‘-tri-O-
acetyl)--D-glucuronic acid methyl ester (400 
MHz, 298 K, J in Hz, in acetone-d6) 
Figure 33: Structure of 3,5-di-O-acetyl-kaempferol-7,4´-di-O-(2‘‘, 
3‘‘, 4‘‘-tri-O-acetyl)--D-glucuronic acid methyl ester 
State of aggregation white solid 
Amount [mg] 28.0 
Yield [%] 11 
m/z [M+H]
+
 1003.2359 
Calc m/z [M+H]
+
 1003.2350 
 
Table 25: Data of of 3,5-di-O-acetyl-kaempferol-7,4´-di-
O-(2‘‘, 3‘‘, 4‘‘-tri-O-acetyl)--D-glucuronic acid methyl 
ester 
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3.3.2.4 Synthesis of Kaempferol-7-O--D-glucuronide 
 
3,5-Di-O-acetyl-kaempferol-7-O-(2‘‘,3‘‘,4‘‘-tri-O-acetyl)--D-glucuronic acid methyl ester 
(11.2 mg, 16.3 µmol) was dissolved in 10 mL 50% aq. MeOH. After the addition of 0.3 mL aq. 
sodium carbonate (0.5 M), the reaction mixture was stirred at room temperature for 1 h. 
After cooling the pH was ajusted ≤ 3 with Dowex 50 W X 4 resin. The mixture was filtrated 
and the residue was washed with 10 mL 50% aq. MeOH and 10 mL MeOH. The crude 
product was purified by semipreparative HPLC. 
Chromatographic parameter: 
Instrument:  Semipreparative HPLC 
Column:  Knauer, Vertex, 16 x 250 mm 
Stationary phase: Eurospher-100 C18-7 µm 
Mobile phase:  A: H2O+0.1% TFA, B: Acetonitrile+0.1% TFA 
Application:  Liquid injection in 15% aqueous acetonitrile 
Fractionation:  19 min 
Gradient:  0 min: 10% acetonitrile+0.1% TFA 
   15 min: 45% acetonitrile+0.1% TFA 
   16 min: 90% acetonitrile+0.1% TFA 
   16-18 min: 90% acetonitrile+0.1% TFA 
   19 min: 10% acetonitrile+0.1% TFA 
Flow:   10 mL/min 
Retention Time (tR): 14.0 min 
λmax [nm] at tR: 225, 251, 262, 364 
File:   2012-03/174-175 
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Position 
1
H 
13
C  
2  147.9 
3  136.2 
4  176.2 
5  160.5 
6 6.43 (1H, d, 2.2) 98.9 
7  162.5 
8 6.80 (1H, d, 2.1) 94.6 
9  156.1 
10  105.1 
1´  121.8 
2´,6´ 8.04 (2H, d, 9.0) 130.0 
3´,5´ 6.93 (2H, d, 9.0) 115.8 
4´  159.5 
1´´ 5.22 (1H, d, 7.6) 99.4 
2´´ 3.30-3.26(1H, m) 72.9 
3´´ 3.33 (1H, t, 8.9) 75.6 
4´´ 3.39 (1H, t, 9.3) 71.4 
5´´ 4.03 (1H, d, 9.6) 75.5 
6´´  170.3 
 
Table 26: 
1
H and 
13
C NMR spectral data of kaempferol-7-O-
-D-glucuronide (600/150 MHz, 298 K, J in Hz, in DMSO-d6) 
State of aggregation yellow solid 
Amount [mg] 5.0 
Yield [%] 66 
m/z [M-H]
-
 461.0726 
Calc m/z [M-H]
-
 461.0725 
λmax in acetonitrile 
252.0, 267.0, 323.0 
365.0 
Molar absorptivity (n=3) 
[L•mol-1•cm-1] 
14140 
(364.7 nm) 
 
Table 27: Data of kaempferol-7-O--D-glucuronide 
Figure 34: Structure of kaempferol-7-O--D-glucuronide 
glucuronide 
 Synthesis of five expected Kaempferol Metabolites 
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3.3.2.5 Synthesis of Kaempferol-7,4’-di-O--D-glucuronide 
 
3,5-Di-O-acetyl-kaempferol-7,4’-di-O-(2‘‘, 3‘‘, 4‘‘-tri-O-acetyl)--D-glucuronic acid methyl 
ester (28.0 mg, 32.9 µmol) was dissolved in 20 mL 50% aq. MeOH. After the addition of 
0.6 mL aq. sodium carbonate (0.5 M), the reaction mixture was stirred at room temperature 
for 180 min. After cooling the pH was ajusted ≤ 3 with Dowex 50 W X 4 resin. The mixture 
was filtrated and the residue was washed with 20 mL 50 % aq. MeOH and 20 mL MeOH. The 
crude product was purified by semipreparative HPLC. 
Chromatographic parameter: 
Instrument:  Semipreparative HPLC 
Column:  Knauer, Vertex, 16 x 250 mm 
Stationary phase: Eurospher-100 C18-7 µm 
Mobile phase:  A: H2O+0.1% TFA, B: acetonitrile+0.1% TFA 
Application:  Liquid injection in 15% aqueous acetonitrile 
Fractionation:  19 min 
Gradient:  0 min: 10% acetonitrile+0.1% TFA 
   15 min: 45% acetonitrile+0.1% TFA 
   16 min: 90% acetonitrile+0.1% TFA 
   16-18 min: 90% acetonitrile+0.1% TFA 
   19 min: 10% acetonitrile+0.1% TFA 
Flow:   10 mL/min 
Retention Time (tR): 10.0 min 
λmax [nm] at tR: 245, 265, 319, 357 
File:   2012-03/176-177 
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Position 
1
H 
13
C 
2  147.0 
3  136.9 
4  176.5 
5  160.5 
6 6.44 (1H, d, 2.1) 99.0 
7  162.6 
8 6.83 (1H, d, 2.1) 94.7 
9  156.2 
10  105.2 
1´  124.8 
2´,6´ 8.14 (2H, d, 9.0) 129.7 
3´,5´ 7.18 (2H, d, 9.1) 116.4 
4´  158.4 
1´´ 5.17 (1H, d, 7.5) 99.6 
2´´ 3.31-3.27 (1H, m)* 73.0* 
3´´ 3.36-3.31 (1H, m)* 75.8* 
4´´ 3.42-3.37 (1H, m)* 71.5* 
5´´ 3.96 (1H, d, 9.6) 75.5* 
6´´  170.3 
1´´´ 5.22 (1H, d, 7.5) 99.4 
2´´´ 3.31-3.27 (1H, m)* 72.9* 
3´´´ 3.36-3.31 (1H, m)* 75.7* 
4´´´ 3.42-3.37 (1H, m)* 71.4* 
5´´´ 4.03 (1H, d, 9.6) 75.5* 
6´´´  170.3 
 
Table 28: 
1
H and 
13
C NMR spectral data of kaempferol-7,4´-di-O--D-
glucuronide (600/150 MHz, 298 K, J in Hz, in DMSO-d6) 
* signals are exchangeable, COSY suggests: δ(H4´´) > δ(H4´´´),                  
δ(H2´´) > δ(H2´´´) 
 Synthesis of five expected Kaempferol Metabolites 
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Figure 35: Structure of kaempferol-7,4´-di-O--D-glucuronide 
State of aggregation yellow solid 
Amount [mg] 11.3 
Yield [%] 54 
m/z [M-H]
-
 637.1046 
Calc m/z [M-H]
-
 637.1043 
λmax in acetonitrile 
251.0, 267.0,    
318.9, 363.0 
Molar absorptivity (n=3) 
[L•mol-1•cm-1] 
10540 
(363.0 nm) 
 
Table 29: Data of kaempferol-7,4´-di-O--D-
glucuronide 
 Synthesis of five expected Kaempferol Metabolites 
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3.3.3 Synthesis of Kaempferol-3-O--D-glucuronide 
3.3.3.1 Synthesis of Kaempferol-3-O-(2‘‘, 3‘‘, 4‘‘-tri-O-acetyl)--D-glucuronic acid 
methyl ester 
 
Kaempferol (75.0 mg, 262 µmol), potassium carbonate (36.0 mg, 262 µmol, 1 eq) and 1-
bromo-2,3,4-tri-O-acetyl-α-D-glucuronic acid methyl ester (728.0 mg, 1833 µmol, 7 eq) were 
suspended under nitrogen atmosphere and 0 °C in 2.6 mL DMF. The ice bath was removed 
and after 72 h another 36.0 mg of potassium carbonate were added. The reaction mixture 
was stirred overall for 96 h at room temperature. Subsequently, 50 mL of EtOAc were added 
to the reaction mixture, which was extracted two times with 50 mL H2O, each. The organic 
phase was dried under nitrogen stream before the crude product was purified by 
semipreparative HPLC.  
Chromatographic parameter: 
Instrument:  Semipreparative HPLC 
Column:  Knauer, Vertex, 16 x 250 mm 
Stationary phase: Eurospher-100 C18-7 µm 
Mobile phase:  A: H2O, B: acetonitrile 
Application:  Liquid injection in 80% aqueous acetonitrile 
Fractionation:  22 min 
Gradient:  0 min: 25% acetonitrile 
   15 min: 65% acetonitrile 
   18 min: 90% acetonitrile 
   18-20 min: 90% acetonitrile 
   22 min: 25% acetonitrile 
 Synthesis of five expected Kaempferol Metabolites 
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Flow:   10 mL/min 
Retention Time (tR): 15.8 min 
λmax [nm] at tR: 224, 239, 264, 346 
File:   2013-08/207-209 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Position 
1
H 
6 6.21 (1H, d, 2.0) 
8 6.43 (1H, d, 2.0) 
2´,6´ 7.98 (2H, d, 8.9) 
3´,5´ 6.90 (2H, d, 8.9) 
1´´ 5.76 (1H, d, 7.9) 
Sugar proton 5.45 (1H, t, 9.7) 
Sugar proton 5.02 (1H, dd, 8.3, 10.5) 
Sugar proton 4.96 (1H, t, 9.9) 
Sugar proton 4.46 (1H, d, 9.9) 
O-CH3 3.51 (3H, s) 
3x CO-CH3 
(sugar) 
2.02 (3H, s) 
1.99 (3H, s) 
1.97 (3H, s) 
 
 
 
State of aggregation pale yellow solid 
Amount [mg] 14.9 
Yield [%] 9 
m/z [M+H]
+
 603.1343 
Calc m/z [M+H]
+
 603.1344 
 
Table 30: 
1
H NMR spectral data of kaempferol-3-O-
(2‘‘, 3‘‘, 4‘‘-tri-O-acetyl)--D-glucuronic acid methyl 
ester (300 MHz, 298 K, J in Hz, in DMSO-d6) 
 
Table 31: Data of kaempferol-3-O-(2‘‘, 3‘‘, 4‘‘-tri-O-
acetyl)--D-glucuronic acid methyl ester 
Figure 36: Structure of kaempferol-3-O-(2‘‘, 3‘‘, 
4‘‘-tri-O-acetyl)--D-glucuronic acid methyl 
ester 
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3.3.3.2 Synthesis of Kaempferol-3-O--D-glucuronide 
 
 
 
 
 
 
Kaempferol-3-O-(2‘‘, 3‘‘, 4‘‘-tri-O-acetyl)--D-glucuronic acid methyl ester (7.5 mg, 32.9 
µmol) was dissolved in 15 mL 50% aq. MeOH. After the addition of 0.45 mL aq. sodium 
carbonate (0.5 M), the reaction mixture was stirred at room temperature for 150 min. After 
cooling the pH was ajusted ≤ 3 with Dowex 50 W X 4 resin. The mixture was filtrated and the 
residue was washed with 20 mL 50 % aq. MeOH and 20 mL MeOH. The crude product was 
purified by semipreparative HPLC. 
Chromatographic parameter: 
Instrument:  Semipreparative HPLC 
Column:  Knauer, Vertex, 16 x 250 mm 
Stationary phase: Eurospher-100 C18-7 µm 
Mobile phase:  A: H2O+0.1% TFA, B: acetonitrile+0.1% TFA 
Application:  Liquid injection in 5% aqueous acetonitrile 
Fractionation:  19 min 
Gradient:  0 min: 10% acetonitrile+0.1% TFA 
   15 min: 45% acetonitrile+0.1% TFA 
   16 min: 90% acetonitrile+0.1% TFA 
   16-18 min: 90% acetonitrile+0.1% TFA 
   19 min: 10% acetonitrile+0.1% TFA 
Flow:   10 mL/min 
Retention Time(tR): 13.5 min 
λmax [nm] at tR: 222, 263, 348 
File:   2013-08/7 
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Position 
1
H 
13
C  
2  156.3 
3  133.0 
4  177.2 
5  161.1 
6 6.20 (1H, d, 2.1) 98.8 
7  164.2 
8 6.42 (1H, d, 2.0) 93.7 
9  156.3 
10  103.9 
1´  120.6 
2´,6´ 8.14 (2H, d, 8.9) 130.9 
3´,5´ 6.86 (2H, d, 8.9) 115.1 
4´  177.2 
1´´ 5.47 (1H, d, 7.5) 101.1 
2´´ 3.23-3.18 (1H, m) 73.9 
3´´ 3.26-3.22 (1H, m) 75.8 
4´´ 3.35-3.30 (1H, m) 71.5 
5´´ 3.53 (1H, d, 9.6) 75.8 
6´´  169.9 
 
State of aggregation yellow solid 
Amount [mg] 1.7 
Yield [%] 30 
m/z [M-H]
-
 461.0721 
Calc m/z [M-H]
-
 461.0725 
λmax in acetonitrile 267.0, 347.3 
Molar absorptivity (n=3) 
[L•mol-1•cm-1] 
11640 
(267.0 nm) 
 
Table 32: 
1
H and 
13
C NMR spectral data of 
kaempferol-3-O--D-glucuronide (600/150 MHz, 298 
K, J in Hz, in DMSO-d6) 
 
Figure 37: Structure of kaempferol-3-O--D-
glucuronide 
Table 33: Data of kaempferol-3-O--D-glucuronide 
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3.3.4 Synthesis of Kaempferol-7-sulfate 
 
Kaempferol (75.0 mg, 262 µmol) was transferred in a Schlenk flask. N,N'-
Dicyclohexylcarbodiimide (541.0 mg, 2.62 µmol, 10 eq) and tetrabutylammonium 
hydrogensulfate (TBAHS, 136.0 mg, 524 µmol, 2 eq) were dissolved in 2 mL and 250 µL 
pyridine, respectively and added via a septum. The reaction mixture was stirred under 
nitrogen atmosphere and room temperature. After 3 days 4.6 mL of MeOH were added.53 
The dicyclohexylurea precipitates were filtered off and the solvent was removed under 
nitrogen stream. The crude product was purified by flash column chromatography 
Chromatographic parameter: 
Instrument:  Flash chromatography 
Column:  Merck, SuperVarioPrep® D40, 46 x 186 mm 
Stationary phase: Merck, LiChroprep RP-18 25-40 µm, 30 g, 30 x 100 mm + 5 g 
precolumn 
Mobile phase:  A: H2O, B: MeOH 
Application:  Suspension in 30% MeOH 
Fractionation:  35 min 
Gradient:  0 min: 30% MeOH 
   25 min: 75% MeOH 
   30 min: 100% MeOH 
   30-35 min: 100% MeOH 
Flow:   20 mL/min 
Region of retention: 20-25 min, 570–720 mL 
File:   120814-1258-1 
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The combined fractions were dissolved in 2 mL MeOH and the potassium salt of the flavonol 
sulfate was generated by adding 2 mL saturated, methanolic potassium acetate solution. The 
suspension was centrigugated at 3000 rcf for 5 min. The precipitate was purified by 
semipreparative HPLC. 
Chromatographic parameter: 
Instrument:  Semipreparative HPLC 
Column:  Knauer, Vertex, 16 x 250 mm 
Stationary phase: Eurospher-100 C18-7 µm 
Mobile phase:  A: H2O, B: acetonitrile 
Application:  Liquid injection in 10% aqueous acetonitrile 
Fractionation:  15 min 
Gradient:  0 min: 10% acetonitrile 
   10 min: 20% acetonitrile 
   10-12 min: 20% acetonitrile 
   13 min: 10% acetonitrile 
   13-15 min: 10% acetonitrile 
Flow:   10 mL/min 
Retention Time(tR): 9.4 min 
λmax [nm] at tR: 246, 369 
File:   2012-09/192-193 
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Position 
1
H 
1
HLIT 
6 6.55 (1H, d, 2.0) 6.55 (1H, d, 2.0) 
8 6.97 (1H, d, 2.1) 6.98 (1H, d, 2.0) 
2´,6´ 8.06 (2H, d, 8.9) 8.08 (2H, d, 8.9) 
3´,5´ 6.94 (2H, d, 8.9) 6.93 (2H, d, 8.9) 
 
Table 34: 
1
H NMR spectral data of kaempferol-7-sulfate 
(300 MHz, 298 K, J in Hz, in DMSO-d6) compared to 
literature values
53
 
State of aggregation yellow solid 
Amount [mg] 2.6 
Yield [%] 3 
m/z [M-H]
-
 364.9978 
Calc m/z [M-H]
-
 364.9973 
λmax in acetonitrile 249.9, 322.1, 366.1 
Molar absorptivity (n=3) 
[L•mol-1•cm-1] 
9553 
(249.9 nm) 
 
Figure 38: Structure of kaempferol-7-sulfate 
Table 35: Data of kaempferol-7-sulfate 
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Kaempferol-4'-O-β-D-glucuronide                          Kaempferol  
2',6' 3',5' 
8 6 
Figure 39: Superimposed 
1
H NMR spectra of kaempferol and kaempferol-4´-
O--D-glucuronide 
3.4 Results and Discussion 
Synthesis of Kaempferol-4´-O--D-glucuronide 
 
Scheme 1: Synthesis of kaempferol-4´-O--D-glucuronide. Reagents and conditions: (a) benzyl bromide, K2CO3, DMF, 2h;      
(b) 1-bromo-2,3,4-tri-O-acetyl-α-D-glucuronic acid methyl ester, Ag2O, CaSO4, acetonitrile/pyridine, 3.5 h; (c) 
cyclohexene, Pd(OH)2 on charcoal, reflux, 45 min; (d) Na2CO3, MeOH, H2O, 1.5 h. 
The synthesis of kaempferol-4´-O--D-glucuronide started with a Williamson ether synthesis. 
Under alkaline conditions, the organohalide benzyl bromide substitutes to certain hydroxyl 
functions of kaempferol if an appropriate stoichiometry is used. This SN2 reaction was 
accomplished to protect the hydroxyl functions and positions 3 and 7 of the kaempferol as 
benzyl ethers. Although mono- and tri-benzylated side product were generated, the main 
compound in the final reaction mixture was 3,7-di-O-benzyl-kaempferol. In the next step, 
the formation of the glycosidc bond was achieved via a modified Koenigs-Knorr reaction. A 
1-bromo derivate of the 
glucuronic acid was activated 
by silver-I-oxide followed by 
the substitution to the most 
reactive free hydroxyl 
function, which is at position 
4´. After purification, the 
benzyl ether protecting 
groups were removed by a 
transfer hydrogenation. 
Cyclohexene was used as 
hydrogen donor under 
palladium catalysis. In the 
final step, the remaining acetyl protecting groups and the methyl ester were cleaved under 
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alkaline conditions to yield the desired product. The position of the glucuronic acid at the 
flavonol was analyzed by 2D NMR, although the comparison of the 1H NMR data of the 
aglycone and the glucuronide already shows meaningful differences in the chemical shift 
(Figure 39).  
For the aromatic protons which are near the substituted hydroxyl group, higher ppm values 
can be expected. The signals for the protons of the A-ring stay rather unchanged ( 6.45 ppm 
und  6.18 ppm, respectively), whereas the four protons of the B-ring, especially at position 
3´ and 5´ show a downfield shift. These have a chemical shift of 6.92 ppm for the agylcone 
and 7.18 ppm for the kaempferol-4´-O--D-glucuronide. Further on, an additional duplett at 
5.18 ppm with coupling constant of 3J = 7.24 Hz proofs the -configuration of the glucuronic 
acid. 
Further confirmation on the structure was acquired by the analysis of 2D NMR data. Some 
key sections of this data are presented in Figure 40 and Figure 41. 
 
Figure 40: Section of 
1
H,
13
C HMBC spectral data of 
kaempferol-4´-O--D-glucuronide 
 
Figure 41: Section of 
1
H,
1
H NOESY spectral data of 
kaempferol-4´-O--D-glucuronide 
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Figure 40 shows the cross peaks in the 1H,13C HMBC spectra of the carbon at 158.3 ppm with 
the aromatic protons of the B-ring (H-2´, -6´, -3´, -5´) and the anomeric proton 1´´ (5.18 ppm) 
of the glucuronic acid as 2J and 3J couplings, respectively. This carbon can be associated to 
the position 4´, because all other carbon of the B-ring can be excluded based on HSQC 
(exclusion of 2´,3´,5´,6´) and the chemical shift in combination with HMBC (exclusion of 1´). 
Further on, another correlation based on the Nuclear Overhausen Effect (NOE) confirms 
spatial proximity between the anomeric proton and the proton pairs H-2´, -6´ and H-3´, -5´ 
(Figure 41). Consequently, it can be assumed that the distance between the protons is ≤ 5 Å, 
which makes the detectable energy transfer of the NOE possible. The analytical data clearly 
verify that the product of the synthesis was kaempferol-4´-O--D-glucuronide. 
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Synthesis of Kaempferol-7-O--D-glucuronide and Kaempferol-7,4´-di-O--D-glucuronide 
 
 
 
 
 
 
 
 
The synthesis of kaempferol-7-O--D-glucuronide and kaempferol-7,4´-di-O--D-glucuronide 
started with a peracetylation of kaempferol. All four hydroxyl groups of the aglycone were 
protected as acetic acid esters under alkaline conditions with acetic anhydride. The product 
was treated with Burkholderia cepacia lipase. The addition of 1-butanol enabled a selective 
transesterification, wherein the protecting groups at position 7 and 4´ were removed, to give 
the 3,5-diacetylated product. The following modified Koenigs-Knorr glucuronidation was 
accomplished in a certain stoichiometry to yield in the formation of both desired products, 
which were again deprotected unter alkaline conditions. 
  
Scheme 2: Synthesis of kaempferol-7-O--D-glucuronide and kaempferol-7,4´-di-O--D-glucuronide. Reagents and 
conditions: (a) acetic anhydride, pyridine, reflux, 5 h; (b) Burkholderia cepacia lipase, 1-BuOH, THF, 42 °C, 8 days; (c) 1-
bromo-2,3,4-tri-O-acetyl-α-D-glucuronic acid methyl ester, Ag2O, CaSO4, acetonitrile, 4 h; Na2CO3, MeOH, H2O, 1-3 h 
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NMR Analysis of Kaempferol-7-O--D-glucuronide 
The comparison of the 1H NMR spectral data of the glucuronidated product with 1H data of 
kaempferol shows evidence enough to conclude a substitution at the C-7. 
 
 
 
 
 
 
 
 
 
 
Analogously to the signals of kaempferol-4´-O--D-glucuronide showing higher ppm values 
for the aromatic protons of the B-ring due to substitution, Figure 42 shows the same effect 
for the aromatic protons of the A-ring. For kampferol-7-O--D-glucuronide, the protons of 
the B-ring remained almost unchanged ( 6,92 ppm; 8,04 ppm). The substitution with a 
glucuronic acid at position 7 leads for H-8 to a higher chemical shift of 6.80 pm (6.44 ppm for 
the aglycone). A similar effect can be detected for H-6, where the signal was found at 6.43 
ppm for the glucuronide, compared to 6.18 ppm for kaempferol. 
  
Kaempferol-7-O-β-D-glucuronide                 Kaempferol  
2',6' 
3',5' 
8 
6 
Figure 42: Superimposed 
1
H NMR spectra of kaempferol and kaempferol-7-O--D-glucuronide 
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Some key correlations of the 2D NMR analysis are presented in Figure 43 and Figure 44. The 
carbon at position 7 shows cross peaks with the two aromatic protons of the A-ring and the 
H-1´´ of the glucuronic acid. The latter also gives, due to spatial proximity, a signal in the 
NOESY with H-6 and H-8. 
 
 
Figure 43: Section of 
1
H,
13
C HMBC spectral data of 
kaempferol-7-O--D-glucuronide 
 
Figure 44: Section of 
1
H,
1
H NOESY spectral data of 
kaempferol-7-O--D-glucuronide 
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NMR Analysis of Kaempferol-7,4´-di-O--D-glucuronide 
The mentioned downfield shift of the aromatic protons in kaempferol-4´-O--D-glucuronide 
and kaempferol-7-O--D-glucuronide was consequently also detected and confirmed for 
kaempferol-7,4´-di-O--D-glucuronide. Resonances at higher ppm values were measured for 
all aromatic protons, the two of the A-ring and the four of the B-ring (Figure 45). Further on, 
two additional dubletts at 5.17 and 5.22 ppm proof the presence of two anomeric protons. 
The coupling constant is 7.5 Hz for each, which indicated the -configuration of the 
glucuronic acids.  
 
 
 
 
 
 
 
 
In the 1H,13C-HMBC (Figure 46) the coupling between von C-4´ with H-2´, H-6´ (8.14 ppm) 
and H-3´, H-5´ (7.18 ppm) as well as to the anomeric proton at 5.17 ppm is clearly visible. 
Analogously, C-7 shows cross peaks with H-8 (6.83 ppm), H-6 (6.44 ppm) and the other 
anomeric proton at 5.22 ppm. The cross peak which is not marked based on a correlation 
between C-5 and H-6. 
 
  
Kaempferol-7,4´-di-O-β-D-glucuronide                                   Kaempferol  
Figure 45: Superimposed 
1
H NMR spectra of kaempferol and kaempferol-7,4´-di-O--D-glucuronide 
2',6' 
3',5' 
8 
6 
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The 1H,1H-NOESY spectral data again confirms the position of the glucuronic acids (Figure 
47). 
 
 
 
 
 
 
 
 
 
Figure 46: Section of 
1
H,
13
C HMBC spectral data of kaempferol-7,4´-di-O--D-glucuronide 
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Figure 47: Section of 
1
H,
1
H NOESY spectral data of kaempferol-7,4´-di-O--D-
glucuronide 
2´,6
´ 
3´,5´ 8 
 
6 
 
4´ 
7 
2J 3J 3J 
3J 2J 2J 
1´´ 
 
1´´´´ 
 
 Synthesis of five expected Kaempferol Metabolites 
~ 81 ~ 
  
Kaempferol-3-O-β-D-glucuronide                    Kaempferol  
2´,6´ 
3´,5´ 
8 
1´´ 
 
6 
Figure 49: Superimposed 
1
H NMR spectra of kaempferol and kaempferol-3-O--D-
glucuronide 
Synthesis of Kaempferol-3-O--D-glucuronide 
 
Figure 48: Synthesis of kaempferol-3-O--D-glucuronide. Reagents and conditions: (a) 1-bromo-2,3,4-tri-O-acetyl-α-D-
glucuronic acid methyl ester, K2CO3, DMF, 4 d; following deprotection: Na2CO3, MeOH, H2O, 2 h. 
The synthesis of kaempferol-3-O--D-glucuronide could be accomplished within two steps, 
because no primary protection of the aglycone with acetyl- or benzyl groups was necessary. 
The previous presented glucuronidation by the use of a modified Koenigs-Knorr reaction did 
not result in the formation of appreciably amounts of any glucuronidated product with this 
starting materials. In contrast, the desired product was generated under alkaline conditions. 
Further on, these reaction conditions are most probable also useful for the synthesis of 
kaempferol-7-O--D-glucuronide, which presence can be expected in a fraction after 
chromatographic purification, due to corresponding shifts in the 1H NMR data. 
Concering kaempferol-3--D-glucuronide, no remarkable downfield shifts of the aromatic 
protons of the A-ring and B-ring were observed in comparison to the aglycone, what could 
be confirmed by the 1H 
NMR data (Figure 49). 
The presence of the 
additional dublett at 
5.33 (J = 7.4 Hz) again 
verified the -
configuration of the 
glucuronic acid.  
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Figure 50: Section of 
1
H,
13
C HMBC spectral data of kaempferol-3-O--D-glucuronide 
Further on, no correlations in the 1H,13C-HMBC are visible between the anomeric proton 1´´ 
and any carbon of the A- or B-ring of the flavonol. Just one cross peak with a carbon was 
detected, which could be assigned to C-3 (Figure 50).  The  1H,1H-NOESY spectral data did not 
show any correlation between the aromatic protons and the proton 1´´. 
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Figure 52: Superimposed 
1
H NMR spectra of kaempferol and kaempferol-7-sulfate 
2´,6´ 3´,5
´ 
8 6 
8 
6 
Kaempferol-7-sulfate                               Kaempferol  
Synthesis of Kaempferol-7-sulfate 
 
 
 
 
 
The synthesis of kaempferol-7-sulfate was accomplished according to literature, but the 
yield in the present study is much lower (3%    49%).59 Barron et al. performed the reaction 
at 4 °C, whereas in the present work the mixture was stirred at room temperature. This 
increase should, also with regard to the published reaction, enforce the additional sulfation 
at the hydroxyl functions 3 and 4´, if the stoichiometry concering TBAHS is adequate because 
the 7-OH group is still the most reactive one. It is more conceivable that the problem of the 
low yield can be found in the workup of the crude product. Although different 
chromatographic separation techniques were applied as Barron et al. worked with Sephadex 
LH-20 and in the present study RP-18 silica gel was used, this step should not cause 
problems. Rather the conversion of the TBA salt to the potassium salt might be the crucial 
step. The formation of the potassium salt precipitate by the addition of methanolic 
potassium acetate is probably incomplete. Further experiments have to be made to avoid 
this significant loss during workup. The presence of a sulfate moiety does not show any 
additional signal in the 1H 
NMR, but the electron 
withdrawing effect of this 
group results in a 
downfield shift of H-6 and 
H-8 (Figure 52). The NMR 
data are in agreement 
with literature and 
further confirmation was 
achieved by HRMS data.  
Figure 51: Synthesis of kaempferol-7-sulfate. Reagents and conditions: (a) tetrabutylammonium 
hydrogensulfate, N,N´-dicyclohexylcarbodiimide, pyridine, 2 d; KAc, MeOH. 
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4 Quantification of Plasma Metabolites 
4.1 Introduction 
After oral consumption of flavonol glycosides, the compounds will be hydrolyzed to the 
corresponding sugars and 
the aglycone. This cleavage 
can already occur in the 
oral cavity,63 but takes 
place mainly in the jejunum 
(Figure 53).64,65 The 
enzymes, which catalyze 
this reaction are the 
cytosolic -glucosidase 
(CBG) and the lactase 
phlorozin hydrolase. The 
latter is a trans-membrane 
protein, located at the 
apical side of the 
enterocytes and enables 
the hydrolysation in the 
intestinal lumen.65 The resulting aglycone has due to its lipophilicity the opportunity to pass 
the membrane by passive diffusion.66 Another way for the uptake of the flavonoid glycoside 
itself into the enterocyte is the active transport via a sodium-dependent glucose 
transporter.66 A following cleavage of the glycosidic bond by the CBG results also in the 
formation of the free sugar and the aglycone, which can further be metabolised. Phase-I-
metabolism, including among other derivatisations, the attachment of a hydroxyl function by 
Cytochrom P450, seems to play a negligible part in kaempferol metabolism. At least, 
kaempferol already has four hydroxyl functions with different reactivity and can thus 
undergo directly phase-II-metabolism by phenolsulfotransferase (SULT, enterocytes, 
hepatocytes) and/or uridine-5`-diphospho-glucuronosyltransferase (UGT, enterocytes 
(UGT1A10), hepatocytes).67,66 The consequence is the possible conjugation of kaempferol 
with a sulfate moiety and/or a glucuronic acid. Due to the number of hydroxyl functions, 
Figure 53: Proposed pathways for small intestinal absorption and metabolism of 
quercetin glucosides. Annotations: LPH, lactase phloridzin hydrolase; SGLT1, 
sodium-dependent glucose transporter 1; MRP-2, multidrug resistance-associated 
protein-2. 1, Quercertin glucosides are directly absorbed via SGLT-1 followed by 
cytosolic -glucosidase hydrolysis or excretion into the lumen via MRP-2; 2, 
Quercertin glucosides are hydrolyzed by luminal LPH followed by the absorption 
of resulting aglycones via lipophilicity-dependent simple diﬀusion. 3, Quercertin 
aglycone in the mucosa is converted into its conjugated metabolites by UDP-
glucuronosyltransferase and/or phenol sulfotransferase. 4,5, Conjugated 
metabolites are transported into the circulatory systems (4) or are excreted into 
the lumen (5).
109
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Figure 54: Potential routes of flavonoid absorption, metabolism and elimination
110
 
different metabolites are conceivable. These compounds can directly be eliminated, but they 
also undergo enterhepatic circulation (Figure 54), which may include again cleavage to form 
the aglycone, followed by a conjugation with potentially other substituents at different 
positions. 
 
 
 
 
 
 
 
Singh et al. (2010) suggested the formation of three kaempferol monoglucuronides after the 
incubation with UDP-glucuronosyltransferase isoforms. The position of substitution was 
analyzed according to different λmax.
68 The assumed major metabolites were kaempferol-3-
O- and the kaempferol-7-O--D-glucuronide. In general this was detected by a hypsochromic 
shift of band I in the UV spectra (Table 40). 
 
 
 
 
Zhao et al. (2010) have discussed the presence of kaempferol-7-O--D-glucuronide and 
kaempferol-3,7-di-O--D-glucuronide in bile and blood of rats, respectively.69 Due to the fact 
that no characteristic fragmentation peaks of the diglucuronide were reported, the position 
of the substituents is not clear. Further on, the formation of kaempferol-7-O--D-
glucuronide is not confirmed by a reference substance, but by the fact, that the 7-OH 
flavone was predominantly conjugated to form a glucuronide in cultured hepatocytes.70  
Compound Band II λmax [nm] Band I λmax [nm] 
Δ Shift to aglycone 
of Band I [nm] 
Kaempferol 262.9 366.1  
3-GluA 262.9 348.5 -17.6 
7-GluA 262.9 366.1 no change 
4´-GluA 262.9 357.8 -8.3 
 
Table 36: Hypsochromic shifts of kaempferol glucuronides
68 
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4.2 Material and Methods 
4.2.1 Consumable Material 
4.2.1.1 Solvents 
 H2O, deionised, further purified by membraPure, Astacus, MembraPure GmbH, 
Berlin, Germany 
 Acetonitrile, LiChrosolv®, ≥ 99.9%, Merck KGaA, Darmstadt, Germany 
 Tetrahydrofuran, LiChrosolv®, 99.9%, Merck KGaA, Darmstadt, Germany 
4.2.1.2 Chemicals 
 Acetic acid, ≥ 99.8%, Merck KGaA, Darmstadt, Germany 
 Baicalin, ≥ 99%, Extrasynthese, Lyon, France 
 Kaempferol-3-O--D-glucuronide, ≥ 98%, Extrasynthese, Lyon, France 
 L-Ascorbic acid, 99%, Sigma-Aldrich, Steinheim, Germany 
 Sodium acetate, Merck KGaA, Darmstadt, Germany; for sodium acetate buffer, 
2 M, pH = 4.7 (adjusted with acetic acid); before use, addition of ascorbic acid 
(10 mg/mL) 
 Sulfatase, from Helix pomatia, ≥ 10000 U/g, Sigma-Aldrich, Steinheim, Germany 
 Trifluoroacetic acid, 99%, Sigma-Aldrich, Steinheim, Germany 
 -Glucuronidase, type B-10, from bovine liver, ≥ 10100 U/g Sigma-Aldrich, 
Steinheim, Germany 
4.2.1.3 Others 
 Eppendorf tubes 3810X, 1.5 mL, Eppendorf AG, Hamburg, Germany 
 Syringe filter unit, Perfect-Flow (r), regenerated cellulose, 0.2 µm, 13 mm, 
WICOM Germany GmbH, Heppenheim, Germany 
 Syringe Injekt®-F, 1 mL, B.Braun Melsungen AG, Melsungen, Germany 
4.2.2 Instruments 
 Pipettes, 0.5-10 µL, 10-100 µL, 100-100 µL, Eppendorf AG, Hamburg, Germany 
 Vortex mixer VV3, VWR, Darmstadt, Germany 
 Centrifuge, Jouan BR4i multifunction centrifuge, Thermo Electron Corporation, 
Waltham, MA, USA 
 Mass spectrometer: 
 Q-TOF 6540 UHD, Agilent, Santa Clara, USA 
 Electrospray ionization (ESI) 
 Analytical HPLC 
 Column: Hibar® 250-4, Purospher® STAR, RP18e (5 µm), Column No.: 
027444, Merck KGaA, Darmstadt, Germany 
 Precolumn: LiChroCART® 4-4, Purospher® STAR, RP18e (5 µm), Merck 
KGaA, Darmstadt, Germany 
 Pump: Hitachi L-2130, VWR, Darmstadt, Germany 
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 Autosampler: Hitachi L-2200, VWR, Darmstadt, Germany 
 Column Oven: Hitachi L-2350, VWR, Darmstadt, Germany 
 Diode Array Detector: Hitachi L-2455, VWR, Darmstadt, Germany 
 Software, EZChrom Elite, Version 3.3.2 SP2, VWR, Darmstadt, Germany 
4.2.2.1 Chromatographic Separation 
The following method was used for plasma quantification. For HPLC-MS analysis of plasma 
samples the same gradient was used, but other solvents, namely A: 10 mM NH4HCO3 in H2O, 
B: acetonitrile. 
Instrument:  Analytical HPLC 
Oven:   23 °C 
Thermo Unit:  4 °C 
Column:  Precolumn: LiChroCART® 4-4, Purospher® STAR RP-18e (5 µm) 
Main Column: Hibar® 250-4, Purospher® STAR RP-18e (5 µm) 
Mobile Phase:  A: H2O/THF 98.3/1.7 + 0.1% TFA, B: acetonitrile  
Injection Volume: 20 µL 
Flow   1.1 mL/min 
Gradient:  0 min: 10% acetonitrile 
0-2 min: 10% acetonitrile  
   9 min: 25% acetonitrile 
   17 min: 35% acetonitrile 
   22 min: 50% acetonitrile 
   25 min: 100% acetonitrile 
   25-30 min: 100% acetonitrile 
   32 min: 10% acetonitrile 
   32-39 min: 10% acetonitrile 
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4.2.3 Sample Preparation 
All plasma samples were frozen at -80 °C and were just defrosted to form aliquots for sample 
preparation. Unless otherwise indicated, the samples were treated at 0 °C. 
 50 µL plasma aliquot 
 Addition of 0.5 µL aqueous ascorbic acid solution (c = 202 mmol/L, cf = 1 mmol/L) 
 Addition of the internal standard (IS): 3 µL baicalin solution (c = 50 µmol/L in 
acetonitrile) 
 Addition of 47.5 µL acetonitrile for protein precipitation 
 Vortex at 4 °C for 5 min (Level 4.5) 
 Centrifugation at 4 °C for 10 min at 14000 rpm 
 Filtration: 0.2 µm, regenerated cellulose 
 HPLC analysis 
4.2.4 Calibration Curve Parameter 
For each of the expected metabolite, namely kaempferol-3-O--D-glucuronide, kaempferol-
7-O--D-glucuronide, kaempferol-4’-O--D-glucuronide, kaempferol-7,4’-di-O--D-
glucuronide, kaempferol-7-sulfate and the aglycone kaempferol, a calibration curve was 
determined based on the following parameters. 
 Three times weight of each compound 
 Stock solution in DMSO with c = 50 mmol/L 
 2nd stock solution: dilution with acetonitrile to c = 50 µmol/L 
 Mixture of equal volumes of each 2nd stock solution  3rd stock solution 
 1, 2, 2.5, 3, 4, 5, 6, 7 and 9 µL of 3rd stock solution were added to the appropriate 
amount of blank plasma matrix (supernatant after protein precipitation, 
centrifugation and filtration) to a final volume of 101 µL 
 Addition of 0.5 µL aqueous ascorbic acid solution (c = 202 mmol/L, cf = 1 mmol/L) 
 Addition of the internal standard (IS): 3 µL baicalin solution (c = 50 µmol/L in 
acetonitrile) 
 Basically, 27 values were measured for each compound (9 concentrations), which 
were corrected according to the Limit of Quantification 
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4.2.5 Tentative Investigation with Glucuronidase and Sulfatase 
 50 µL of plasma 
 Addition of 5 µL glucuronidase (10 mg/mL in sodium acetate buffer) or 5 µL 
glucuronidase (10 mg/mL in sodium acetate buffer) + sulfatase (1.6 mg) 
 Incubation for 2 h at 37 °C and 5% CO2 in the dark 
 Addition of 55 µL acetonitrile for protein precipitation 
 Workup according to 4.2.3 Sample Preparation  
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4.3 Results and Discussion 
For the workup of the plasma samples, a method was developed fullfilling the following 
prerequisites: 
 Recovery ≥ 90 % 
 Fast method  avoiding rotation evaporater, centrifugal evaporator or nitrogen 
stream 
 Least possible dilution of the plasma samples with organic solvent for protein 
precipitation and thus avoiding an unnecessary decrease in the concentration of 
metabolites with regard to the limit of quantification (LOQ) 
For the method development baicalin was added to blank plasma. Acetonitrile was applied 
as one volume equivalent for protein precipitation. The workup procedure was followed by a 
modified HPLC method71 to evaluate the LOQs and the recovery of all reference substances. 
The chromatographic analyses showed a good separation of the reference substances and 
the internal standard (Figure 55). The formation of a double peak for kaempferol-7,4-di-O--
D-glucuronide required an analysis by HPLC-MS. Thereby, it could be confirmed that the 
double peak is assignable to one m/z value and thus be regarded and integrated as one 
peak. The resulting limits of quantification for all the expected metabolites are presented in 
Table 37.  
 
 
 
 
 
 
 
 
Compound 
tR
 
[min] 
Recovery 
[%] 
LOQ 
[ng/mL] 
f(x) R
2
 
Interday 
precision 
(n = 6) 
[%] 
Intraday 
precision 
(n = 6) 
[%] 
7,4´-DigluA 11.2 84 ± 14 ~ 130 3.8364x – 0.0474 0.996 12.0 11.8 
3-GluA 14.5 92 ± 16 ~ 100 2.5360x + 0.1723 0.959 9.1 7.6 
7-GluA 15.3 83 ± 10 ~ 60 5.2085x + 0.1163 0.989 10.4 4.6 
4`-GluA 16.2 70 ± 7 ~ 100 4.0474x + 0.2827 0.981 13.4 8.8 
Baicalin, IS 16.6 106 ± 10    5.5 1.3 
7-Sul 17.0 139 ± 26 ~ 120 1.5873x + 0.1473 0.933 9.1 11.3 
Kaempferol 23.5 83 ± 10 ~ 50 5.7094x + 0.1018 0.990 6.4 10.3 
 
Table 37: Chromatographic and analytical data of the references 
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7,4´-DigluA 
637.1039 3-GluA 
461.0720 
7-GluA 
461.0724 
4'-GluA 
461.0721 
Baicalin 
445.0773 
7-Sul 
364.9971 
Kaempferol 
285.0403 
Figure 55: HPLC analysis of all references and the internal standard after addition to blank plasma and 
usual workup. MS data were obtained from a separate run. CC according to 4.2.2.1  
For the following in vivo study, the four predominant kaempferol glycosides in the Ginkgo 
folium extract EGb 761® were administered to Spraque Dawley rats equal to the dosage of 
600 mg/kg of the extract. As already described in the extract quantification, (page 42) 
kaempferol rutinoside has the highest content and was consequently used in the highest 
dose. For each of the five time points (1, 2, 4, 8 and 24 h) the plasma samples of five rats 
were taken. Unfortunately, only the plasma samples after administration of kaempferol 
rutinoside could be used for identification and quantification of the major metabolites by 
HPLC-UV. The other ones, which were obtained after a single dose of kaempferol biloside, 
acylated kaempferol biloside and kaempferol triglycoside, respectively, were below the limit 
of detection. This is based in the different contents of the kaempferol glycosides in the 
extract and consequently different dosage. 
To make this more obvious, Table 38 illustrates dosage and percentage of each kaempferol 
glycoside and the corresponding kaempferol content compared to the total kaempferol 
(glycosides) content. Beside, it should be noted, that this calculation based on an 
approximation which does not regard the other four kaempferol glycosides in EGb 761®, 
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which could be detected by HPLC-MS analysis. But as already shown, these compounds are 
present in much lower contents in the extract. Nevertheless, the knowledge on the content 
of the four low concentrated kaempferol glycosides is not necessary if just the distribution of 
the kaempferol dosage for the rutinoside, biloside, triglycoside and acylated biloside is 
regarded. 
 
This listing shows, that the other three kaempferol glycosides were administered in more or 
less half of the dosage compared to kaempferol rutinoside, if the percentage of the aglycone 
is regarded (last line of Table 38). Due to this difference, the presence of the corresponding 
metabolites had to be confirmed by HPLC-MS. A comparison of the corresponding retention 
times and the m/z values with the reference substances is presented below. 
 
 
 
 
 
 
 
 
  Rutinoside Biloside Triglycoside Acyl. Biloside 
Content in EGb 761
®
 [% w/w] 2.17 0.89 1.58 1.59 
M [g/mol] 594.16 594.16 740.22 740.20 
Dosage for in vivo study [mg/kg] 13.0 5.3 9.5 9.5 
Content based on the four 
kaempferol glycosides [% w/w] 
34.83 14.29 25.36 25.52 
≙ Calculated content of 
kaempferol [% w/w] 
38.72 15.88 22.63 22.77 
 
Table 38: Content of four kaempferol glycosides in EGb 761®, resulting dosage for in vivo study and approximation of the 
kaempferol (glycoside) percentages in EGb 761® 
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Unknown       
phase-II-metabolite 3-GluA 7-GluA 
Figure 56: Comparison references (green) and plasma sample (black, 4 h) by HPLC-UV at 358 nm. CC according to 4.2.2.1 
4.3.1 Identification of Kaempferol Metabolites  
Kaempferol rutinoside was administered at a concentration of 13 mg/kg. After sample 
workup and HPLC-UV analysis, two signals in the chromatogram could be assigned to the 
appropriate peaks of the reference substances (Figure 56).  
The coelution of two compounds in the plasma with the reference substances kaempferol-3-
O--D-glucuronide (14.6 min) and kaempferol-7-O--D-glucuronide (15.3 min) confirmed the 
presence of these metabolites in vivo. Further on, another phase-II-metabolite of 
kaempferol was detected at 11.6 min, which cannot be assigned to the expected 
kaempferol-7,4´-di-O--D-glucuronide (11.2 min) due to the difference in the retention time. 
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Kaempferol-7-sulfate,  
tR = 17.0 min 
Unknown sulfate, 
tR = 17.3 min 
Figure 58: HPLC-UV at 358 nm, test workup of plasma samples (4 h) with glucuronidase compared to references. CC 
according to 4.2.2.1 
 
usual work up 
Glucuronidase+ 
Sulfatase 
Glucuronidase 
Kaempferol 
Figure 57: HPLC-UV at 358 nm, test workup of plasma samples (4 h) with glucuronidase and/or sulfatase compared to 
unhydrolyzed sample. CC according to 4.2.2.1 
In order to get an evidence for the identification of this metabolite, one exemplarily chosen 
plasma sample was treated once with glucuronidase/sulfatase and once solely with 
glucuronidase. In both cases, the signals for the two monoglucuronides and the unknown 
metabolite disappeared and almost the same integral for the resulting kaempferol aglycone 
was measureable (Figure 57).  
But interestingly, after the incubation with solely glucuronidase, a further peak occured at a 
retention time of 17.3 min (Figure 58). Due to the difference in the retention time, this signal 
cannot be assigned to kaempferol-7-sulfate (17.0 min).  
Glucuronidase 
 References 
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Assuming that this peak disappeared after glucuronidase/sulfatase hydrolysis (Figure 57), 
the corresponding compound is most probably conjugated with a sulfate moiety. Further on, 
a missing increase concerning the kaempferol integral leads to the conclusion, that 
unfortunately, the hydrolysis products of the corresponding compound after treatment with 
glucuronidase/sulfatase are unkown. Nevertheless, it can be said that the unkown phase-II-
metabolite of kaempferol must be substituted with at least one glucuronic acid and at least 
one sulfate group. In order to get more structural information and with regard to the plasma 
samples which were under the LOD by HPLC-UV, an investigation by HPLC-MS was 
accomplished. 
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4.3.2 Plasma Analysis by HPLC-MS 
The plasma samples which were obtained after the oral administration of the following 
kaempferol glycosides were not quantifiable by HPLC-UV, nor any metabolites could be 
detected with this method. 
 3-O-(2-O, 6-O-Bis(α-L-rhamnosyl)--D-glucosyl)kaempferol (Triglycoside) 
 3-O-(2-O-(-D-glucosyl-α-L-rhamnosyl)kaempferol (Biloside) 
 3-O-(2-O-(6-O-(p-Hydroxy-trans-cinnamoyl)--D-glucosyl)-α-L-
rhamnosyl)kaempferol (Acylated Biloside) 
In consequence, one plasma sample for each compound was chosen exemplarily at the time 
point of 4 h and analyzed by a more sensitive HPLC-MS method to identify possible 
metabolites below the LOD in HPLC-UV. The assignment to a certain metabolite was based 
on comparison of retention time and m/z value (Table 39). 
Table 39: Results of HPLC-HRMS of plasma samples compared to references 
 DigluA 
 
GluA-sulfate 3-GluA 4´-GluA 7-GluA 7-Sulfate 
Reference 
3.674 
637.1050 
not available 
calc m/z [M-H]
-
 
541.0294 
8.335 
461.0727 
8.926 
461.0727 
10.142 
461.0728 
15.477 
364.9976 
Rutinoside  
7.458 
541.0295 
8.241 
461.0726 
8.944 
461.0732 
10.126 
461.0730 
15.524 
364.9969 
Biloside  
7.428 
541.0295 
8.261 
461.0732 
8.893 
461.0731 
10.121 
461.0747 
15.531 
364.9976 
Acylated 
Biloside 
 
7.417 
541.0296 
8.254 
461.0725 
8.870 
461.0728 
10.127 
461.0756 
15.488 
364.9974 
Triglycoside  
7.423 
541.0294 
8.325 
461.0728 
8.889 
461.0727 
10.104 
461.0736 
15.435 
364.9973 
 
Overall, the presence of five kaempferol metabolites could be shown, which include the 
three expected monoglucuronides and the sulfate. Further on, a clear assignment of the 
previous mentioned unknown metabolite to a mixed kaempferol glucuronide-sulfate can be 
made. It has to be noted that no signal of a kaempferol diglucuronide was detectable. This 
does not necessarily exclude the presence of a diglucuronide, because the reference 
tR [min] 
m/z 
tR [min] 
m/z 
tR [min] 
m/z 
tR [min] 
m/z 
tR [min] 
m/z 
tR [min] 
m/z 
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substance, kaempferol-7,4´-di-O--D-glucuronide is eluting very early (3.7 min) and thus the 
signal is possibly overlapped by some other peak. 
Finally, it could be shown that the three major metabolites of kaempferol rutinoside, which 
are quantifiable, are: 
 Kaempferol-3-O--D-glucuronide 
 Kaempferol-7-O--D-glucuronide 
 Kaempferol glucuronide-sulfate 
 
4.3.3 Quantification of Kaempferol Metabolites  
In the next step, the plasma levels at three different time points (4 h, 8 h, 24 h) were 
quantified (Table 40). After 1 and 2 h, no kaempferol metabolites could be detected. It has 
to be admit that due to unavailability of a mixed kaempferol glucuronide-sulfate as 
reference substance, this metabolite was, with regard to the synthesized compounds, 
quantifed as the only accessible disubstituted kaempferol, namely kaempferol-7,4´-di-O--D-
glucuronide.  
The plasma samples of five rats for each time point were measured three times. 
Table 40: Plasma levels after the administration of kaempferol rutinoside, measurements were performed in triplicates, 
nmaximal: 5 plasma samples, n.d.: not detectable 
Identified 
metabolite 
c [ng/mL] 
4 hours 
c [ng/mL] 
8 hours 
c [ng/mL] 
24 hours 
AUC 
[ng*h/mL] 
GluA-sulfate 273 ± 83, n=5 294 ± 79, n=5 187 ± 30, n=5 4982 
3-GluA 383 ± 137, n=4 detectable, n=2 n.d., n=5  
7-GluA 30 ± 6, n=3 n.d., n=5 n.d., n=5  
≙ Calculated 
concentration 
of aglycone 
400 ± 94 155 ± 42 99 ± 16  
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Comparison to published data 
In order to discuss the results with published data, just the plasma concentration of the 
aglycone can be regarded, which had to be calculated. 
Within a comparable study from Rangel-Ordóñez et al. in 2010, the extract was administered 
to the same species of rats in a concentration of 600 mg/kg. The resulting maximum plasma 
concentration of kaempferol (acidic 
hydrolysis of the phase-II-metabolites was 
accomplished) was achieved 8 h after 
administration. They reported a value of 
341 ng/mL, but the standard degression is 
not exactly mentioned and can thus just 
be estimated to ± 47 ng/mL based on a 
figure in the publication (Figure 59). In our 
study, the three different kaempferol 
metabolites were quantified, but these 
values can be calculated down to the 
aglycone concentration with the adequate quotient of the molecular masses. The condensed 
calculated kaempferol concentration are shown in the last line of Table 40. Consequently, 
the maximum plasma concentrations of the aglycone presented in literature with a value of 
341 ± 47 ng/mL is very similar to the one in the present study with 400 ± 94 ng/mL. Of 
course, it has to be mentioned that Rangel-Ordóñez et al. administered the extract EGb 761® 
and thus considerably more kaempferol compared to the solely administration of 
kaempferol rutinoside. To be more exact and with regard to Table 38 (page 92), the dosage 
of kaempferol in our study was about 39% compared to the extract administration. In this 
context, it can be estimated that a general maximum plasma concentration ∼350 ng/mL is 
conceivable. This value can on one hand be achieved by the administration of the extract 
and on the other hand just by the content-depended administration of the predominat 
kaempferol glycoside, namely kaempferol rutinoside. 
 
Figure 59: Time course of plasma concentrations of quercetin 
(squares), kaempferol (circles), and isorhamnetin (triangles) 
following a single oral dose of 600 mg/kg of EGb 761®. Each 
point represents the mean ± SEM of six samples
50 
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Nevertheless, the differences in both studies should not be left unattended. Beginning with 
the dosage form, it can be assumed that the following resorption of the compounds is not 
the same for the extract and the pure kaempferol glycoside, respectively. Further on, the 
sample workup is not comparable. Rangel-Ordóñez et al. performed acidic hydrolysis with 
2 M HCl at 90 °C, wherein in the present study no hydrolysis was achieved and the workup 
procedure was accomplished at maximum 4 °C. Finally, it has to be admit that in the present 
study, the mixed kaempferol glucuronide-sulfate was quantified based on a calibration curve 
of kaempferol-7,4´-di-O--D-glucuronide. Consequently, the evaluated plasma concentration 
can have a different value if the exact reference substance is used. 
Application of other Detectors 
Basically, it can be expected that the oral administration of different kaempferol glycosides 
does not result in the formation of different metabolites. Nevertheless, a difference in the 
relative plasma concentration and the time point of maximal plasma concentration are 
conceivable. The most obvious option for this investigation in the present study would be to 
adjust the dosage of the biloside, acylated biloside and triglycoside to the same of rutinoside 
with regard to the kaempferol percentage and thus independent to the content in EGb 761®. 
But further on, the usage of more sensitve detectors can be discussed. 
The use of an electrochemical detector (ED) is basically possible, but it has always be 
regarded that a hydrolysation of the kaempferol metabolites is not desirable in the present 
study design. Nevertheless, it is known that at least a glycosilation at 3-OH has no strong 
effect on the electrochemical behaviour.72 Consequently, one main metabolite in the 
present study, kaempferol-3-O--D-glucuronide, should be combinable with this method. 
Further on, Guo et al. (1997) reported a linear relationship between oxygen radical 
absorbance capacity (ORAC) of aqueous extracts from fruits and vegetable including 
kaempferol glycosides containing plants (e.g. strawberry) and the accessibility for 
electrochemical detection.73 The result of the ORAC assay for some of the synthesized 
kaempferol derivatives are presented further down (page 111). One problem of the ED can 
be the adsorption of electrochemical products to the surface of the electrode and thus a 
decrease of the initial capacity, but a method with HPLC-ED might be worth to try.72 
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The use of a fluorescence detector is conceivable, due to the metal chelating activity of 
kaempferol. For this, a post-column derivatization has to be accomplished, wherein a 
aluminium chelate complexes is formed.50 The disadvantage of this method is, that a free 3-
OH group is essential for the formation of the complex.74 Thereby, one of the major 
metabolites, namely kaempferol-3-O--D-glucuronide is not measurable.  
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Figure 60: Structure of glutathione 
Figure 61: Light microscopic morphology of glutamate-treated HT-22 cells. Cells 
were untreated (A) or treated with 5 mM glutamate for 8 h (B), 10 h (C), or 14 h 
(D) before examination under a phase-contrast microscope. Inset in B shows 
blebs on surface of cells
78
 
5 Pharmacological Characterisation of Kaempferol and Conjugates 
5.1 Introduction 
Neurotoxicity and Neuroprotection Assay 
Neuronal damage can be based on several reasons like i.e. failure in metabolic processes, 
protein impaired mitochondrial function, increased oxidative damage, defect in the 
proteasome system, protein aggregation, changes in iron metabolism or events of 
excitotoxicity and inflammation.75 Oxidative stress might be a reason for at least some of 
these failures and is a consequence of a disturbed homeostasis between generation and 
elimination of reactive oxygen and nitrogen species (ROS, NOS).75 This oxidative stress can 
cause damage of proteins, lipids and nucleic acids as well as a disruption of redox signaling.75 
In the nervous system, the tripeptid glutathione prevents this oxidative stress, because it 
acts as radical scavenger, but also as redox 
modulator of ionotropic receptor activity 
and possibly as neurotransmitter.76 A 
decrease in the glutathione concentration 
can enhance oxidative stress and thus cause ailments like Lou Gehrig´s disease, Parkinson´s 
disease or Alzheimer disease.76 In the neuroprotection assay, the decrease in cellular 
glutathione concentration is 
induced by a high 
extracellular glutamate 
concentration (5 mM). To 
be more specifically, the 
glutamate/cystine anti-
porter is influenced and 
thus, an imbalance in 
cystine homeostasis is 
generated.77 The following 
cell death via the oxidative 
pathway showed 
characteristics of necrosis and apoptosis.78 The morphological mutations during cell death 
can be visualized with an electron microscop (Figure 61). After 8 h the cells begin to shrink, 
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appear more globulary and show little blebs on the surface. Further 2 h later, several cell 
organells seem to be swollen or damaged (endoplasmic reticulum, Golgi-apparatus, 
mitochondria). In contrast, the nuclear morphology is almost stable. After 16-24 h the cells 
disintegrate and just cellular debris can be seen.78 The cell viability can finally be measured 
with the colorimetric MTT assay. 
Investigation of anti-oxidative Activity in a cell-free Assay, ORAC Assay 
In order to have better comparable values for the antioxidative activity of the synthesized 
compounds, the Oxygen Radical Antioxidant Capacity (ORAC) assay was chosen as cell-free 
assay. In general, cell-free systems are easier to handle and also the higher availability and 
reproducibility cannot be denied.79 In the ORAC assay, the compound 2,2'-azobis(2-
amidinopropane) dihydrochloride (AAPH) is used to generated free radicals. These radicals 
degrade the also present fluorescein, which results in a weaker light emission at 535 nm 
(excitation at 485 nm). If the investigated compound shows antioxidant activity, the 
decrease of the emitted light is decelerated.  
Anti-proliferative activity, Proliferation Assay 
Cell proliferation comprises an increase in the number of cells as a consequence of cell 
growth and division. One necessary step for angiogenesis is cell proliferation. Angiogenesis 
includes the growth of new blood vessels during embryogenesis and wound healing, but is 
also supportive in certain diseases like i.e. diabetic retinopathy, psoriasis and rheumatoid 
arthritis and for tumors concerning growing and spreading.80 The ability of some flavonoids 
as anti-cancerogenic compounds is based, among others, in anti-oxidative, pro-apoptotic, 
DNA damaging, anti-angiogenic, and immunostimulatory effects.81 Suppression of the 
abnormal angiogenesis might thus be useful for the therapy of these affections.80  
In the present work, the influence of the synthesized kaempferol derivatives on the cell 
proliferation of human microvascular endothelial cells (HMEC) was examined. It should be 
noted that an anti-proliferative effect on the chosen HMEC-1 cells does not necessarily 
include an anti-angiogenetic activity of the test compound. Among others, also the 
intervention of cell cycle,82 induction of apoptotic cell death83 or a distortion that decreases 
intracellular acidity and/or increases basicity84 are possible essentials for an anti-
proliferative activity. 
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Anti-inflammatory Activity, ICAM-1 Assay 
Inflammation is basically a response of the immune system as a protective event85 and is the 
consequence of several different pathways and signal cascades. One of these pathways 
includes the increase of the ICAM-1 (Intercellular Adhesion Molecule 1) expression. This is 
not uncommon for any kind of inflammation and also chronical inflammatory diseases like 
rheumatoid arthritis, psoriasis and atherosclerosis show an abnormal increase in ICAM-1 
expression. 
Briefly, the cascade starts with the interaction of a macrophage with a pathogen. This 
results, among other reactions, in the release of the tumor necrosis factor α (TNF-α) from 
the macrophage.86 The cytokine TNF-α for his part activates the nuclear transcription factor 
NF-κB via a cascade, starting at a specific receptor at the membrane of the endothelial cells. 
In a next step NF-κB induces the expression of ICAM-1, which enables leukocytes to attach 
and finally pass the endothelial cell layer and thus to reach the location of an infection in the 
tissue. 
Consequently an increase of ICAM-1 can be seen as indication for a proceeding 
inflammation. The informative concentration of ICAM-1 can be visualized by the use of a 
specific antibody, which is labeled with fluorescein isothiocyanate (FITC) and detected via 
fluorescence-activated cell sorting (FACS). 
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5.2 Material and Methods 
5.2.1 Consumable Material 
 Dulbecco´s Modified Eagle Medium, DMEM, gibco®, Life technologies 
coorporation, New York, USA 
 Dulbecco´s Phosphate Buffered Saline (PBS), Sigma-Aldrich, Steinheim, Germany 
 Endothelial cell growth medium + 10% FCS, supplement mix and antibiotics, 
Provitro GmbH, 10117 Berlin, Germany 
 FCS Superior, Biochrom, Berlin, Germany 
 Fluorescein, Merck, Darmstadt, Germany 
 Kaempferol ≥ 99%, Extrasynthese, Lyon, France 
 Mouse anti human CD54: FITC, FITC-labelled mouse antibody against ICAM-1, 0.1 
mg/mL, Biozol, Eching, Germany 
 Parthenolide, ≥ 97%, Calbiochem, Bad Soden, Germany 
 Quercetin, ≥ 98%, Sigma-Aldrich, Steinheim, Germany 
 Sodium dihydrogen phosphate monohydrate, 99.0-102.0%, for 75 mM stock 
solution, Merck, Darmstadt, Germany 
 Thiazolyl blue tetrazolium bromide, ∼98%, for 4 mg/mL in PBS, Sigma-Aldrich, 
Steinheim, Germany 
 Tryphan blue, dye content ∼ 37%, Sigma-Aldrich, Steinheim, Germany 
 TTP® Tissue culture testplate 96F, Techno Plastic Products AG, 8219 Trasadingen, 
Switzerland 
 Tumor Necrosis Factor-α, ≥ 97%, Sigma-Aldrich, Steinheim, Germany 
 H2O, deionised, further purified by membraPure, Astacus, MembraPure GmbH, 
Berlin, Germany 
 Xanthohumol, 98%, Nookandeh Institute, Hamburg, Germany 
 Sodium dodecyl sulfate, 92.5-100.5%, for 10% solution (m/v), Sigma-Aldrich, 
Steinheim, Germany 
 di-Sodium hydrogen phosphate dihydrate, ≥ 99.5%, for 75 mM stock solution, 
Merck, Darmstadt, Germany 
 DMSO, SeccoSolv®, ≥ 99.9%, Merck KGaA, 64271 Darmstadt, Germany 
 Ethanol, ≥ 99.9%, J.T.Baker®, Avantor Performance Materials, Center Valley, PA, 
USA 
 Methanol, EMSURE®, for analysis, 99.9%, Merck KGaA, 64271 Darmstadt, 
Germany 
 Trypsin (1:250)/EDTA (0.5%/0.2%), for 10% solution (v/v) in PBS, Biochrom, Berlin, 
Germany 
 Crystal violett, ACS, Reag. Ph. Eur., for 0.5% solution (m/v) in MeOH, Merck, 
Darmstadt, Germany 
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 tri-Sodium citrate dihydrate, for dissolving buffer, 0.05 M in H2O/EtOH 1:1, 
Merck, Darmstadt, Germany 
 6-Hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox), 98%, Fluka, 
Neu-Ulm, Germany 
 2,2'-Azobis(2-amidinopropane) dihydrochloride (AAPH), 97%, Sigma-Aldrich, 
Steinheim, Germany 
5.2.2 Instruments 
 Autoflow IR Direct Heat CO2 Incubator, Nuaire
TM, Integra Biosciences GmbH, 
Fernwald, Germany 
 FACScalibur™, Becton Dickinson, Heidelberg, Germany 
 Megafuge 1.0R, Thermo Scientific, Waltham, USA 
 Tecan SpectraFluor Plus, Tecan Group Ltd. Crailsheim, Germany 
 IBM® SPSS® Statictics 20 
 
5.2.3 Neurotoxicity and Neuroprotection Assay 
The assay was accomplished according to Kling et al. (2013) in 3 experiments (in 4 parallels): 
Neuroprotectivity/Neurotoxicity Assay 
HT-22 cells were seeded in 96-well plates at a density of 5x103 per well and cultured for 24 h. 
Subsequently, cells were incubated for another 24 h either with medium or the test 
compounds with putative cytoprotective activity either in absence (to test for the 
compounds’ self-toxic effects) or presence (to test for the compounds’ protective potential 
against glutamate induced oxidative stress) of 5 mM glutamate. MTT solution (4 mg/mL in 
PBS) was diluted 1:10 with medium and added to the wells after removal of culture medium. 
The plates were then incubated for another 3 h. Afterwards, supernatants were removed 
and 100 µL of lysis buffer (10% SDS, pH 4.1) was added to the wells. Absorbance at 560 nm 
was determined on the next day using a multiwell plate photometer (Spectra Fluor Plus, 
Crailsheim, Germany). Results of these cell viability assays are expressed as percentage to 
untreated control cells. All compounds were dissolved in DMSO and diluted with fresh 
medium. DMSO concentration was always below 0.1% (v/v). 
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5.2.4 ORAC Assay 
The ORAC assay was accomplished by Gabriele Brunner according to Decker et al. (2012) in 
minimum 4 experiments (in 4 parallels): 
The reaction was carried out in 75 mM phosphate buﬀer (pH 7.4) and the ﬁnal reaction 
mixture was 200 µL. Antioxidant (20 µL) and ﬂuorescein (120 µL, 300 nM ﬁnal concentration) 
were placed in the wells of a black 96-well plate and the mixture was incubated for 15 min at 
37 °C. Then AAPH (Sigma, Steinheim Germany) solution (60 µL; 12 mM ﬁnal concentration) 
was added rapidly. The plate was immediately placed into a Spectraﬂuor Plus plate reader 
(Tecan, Crailsheim, Germany) and the ﬂuorescence was measured every 60 s for … [260] min 
with excitation at 485 nm and emission at 535 nm. 6-Hydroxy-2,5,7,8-tetramethylchroman-
2-carboxylic acid (Trolox, Sigma, Steinheim Germany) was used as standard (1–8 µM, ﬁnal 
concentration). A blank (FL + AAPH) using phosphate buﬀer instead of antioxidant and Trolox 
calibration were carried out in each assay. The samples were measured at diﬀerent 
concentrations … [1-5 µM]. All reaction mixtures were prepared fourfold and at least four 
independent runs were performed for each sample. Fluorescence measurements were 
normalized to the curve of the blank (without antioxidant).87 
5.2.5 ICAM-1 Assay 
The ICAM assay was accomplished by Monika Untergehrer according to Knuth et al. (2011) in 
3 experiments (in 2 parallels):  
Confluent grown human microvascular endothelial cells (HMEC-1)88 were pretreated either 
with … [kaempferol, kaempferol-4´-O--D-glucuronide, kaempferol-7,4´-di-O--D-
glucuronide and kaempferol-7-sulfate], parthenolide (Calbiochem, purity ≥ 97%, 5 µM, 
positive control), or medium (ECGM, endothelial cell growth medium (Provitro) + 10% FKS, + 
antibiotics, + supplements) as a negative control in 24-well plates. Thirty minutes later, 10 
ng/mL TNF-α (Sigma-Aldrich) were added to stimulate the ICAM-1-expression. After 24 hours 
of incubation (New Brunswick Scientific, 37 °C, 5 %CO2), cells were washed with PBS, 
removed from the plate with trypsin/EDTA and fixed with formalin. After incubating with a 
FITC-labelled mouse antibody against ICAM-1 (Biozol) for 20 min, the fluorescence intensity 
was measured by FACS analysis (Becton Dickinson Facscalibur™). ICAM-1-expression of cells 
treated with TNF-α only was set as 100%.89 
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5.2.6 Proliferation Assay 
The proliferation assay was accomplished from Sebastian Schmidt according to 
Schmidt et al. (2012) in one experiments (in 6 parallels): 
The proliferation assay was performed using an SV-40T transfected human microvascular 
endothelial cell line (HMEC-1).88 Cells were incubated at 37 °C under a 5% CO2/95% air 
atmosphere at constant humidity. HMEC-1 cells were seeded in 96-well microplates (100 μL, 
1.5 × 103cells/well) in endothelial cell growth medium with 10% FCS, supplement mix, and 
antibiotics (all from Provitro). After 24 h (time of cell adhesion for seeded cells), the medium 
in a reference plate was removed and the cells were stained with crystal violet solution for 
10 min, providing a baseline value before the start of proliferation. Cells in other plates were 
treated with increasing concentrations of each test compound … [kaempferol, kaempferol-
4´-O--D-glucuronide, kaempferol-7,4´-di-O--D-glucuronide and kaempferol-7-sulfate]. 
After 72 h incubation, cells were stained as previously described. The cells were washed with 
… [deionized] H2O, 100 μL of dissolving buﬀer was added, and the absorbance was measured 
with a Tecan SpectraFluor Plus at 540 nm. A negative control in the absence of drug (pure 
solvent, 0.1% DMSO, in hexaplicates) was included in every 96-well plate and normalized to 
100% proliferation after 72 h. The inhibitory eﬀects of … [kaempferol, kaempferol-4´-O--D-
glucuronide, kaempferol-7,4´-di-O--D-glucuronide and kaempferol-7-sulfate] were 
calculated as % proliferation compared to the no-drug control. … . Xanthohumol was used as 
a positive control.90 
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5.3 Results and Discussion 
For the pharmacological characterisation by the cell based assays, kaempferol, kaempferol-
4´-O--D-glucuronide, kaempferol-7,4´-di-O--D-glucuronide and kaempferol-7-sulfate were 
chosen. The ORAC assay was additionally accomplished with kaempferol-3-O--D-
glucuronide and kaempferol-7-O--D-glucuronide. 
5.3.1 Neurotoxicity and Neuroprotection Assay 
The tested glucuronides and the potassium salt of kaempferol-7-sulfate did not show any 
neurotoxicity or neuroprotectivity within the concentration range of 1-25 µM, which is 
exemplarily shown for kaempferol-7-O-glucuronide in Scheme 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glutamate 5 mM - + + + + + + 
Quercetin 25 µM - - + - - - - 
K-7-O-GluA 
[in µM] 
- - - + + + + 
 Scheme 3: Neurotoxicity and neuroprotectivity of kaempferol-7-O--D-glucuronide. Experiments were 
performed in 3 independent experiments (in 4 parallels each). Data were subjected to one-way ANOVA  
followed by Dunnet‘s multiple comparison post test using IBM SPSS Statistics Software 
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Further on, kaempferol showed a very low neurotoxic in vitro effect at 25 µM and a 
neuroprotectivity already at 5 µM. (Scheme 4) 
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Scheme 4: Neurotoxicity and neuroprotectivity of kaempferol. Experiments were performed in 3 
independent experiments (in 4 parallels each). Data were subjected to one-way ANOVA followed by 
Dunnet‘s multiple comparison post test using IBM SPSS Statistics Software 
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The reason for this effect might be seen in the higher hydrophilicity of the glucuronides and 
the sulfate. The compounds are not able to pass the lipophilic cell membrane and thus, the 
glutamate induced intracellular oxidative stress cannot be reduced by these compounds. 
Nevertheless, the structural essentials for a neuroprotectivity are basically present also in 
the conjugates. Ishige et al. have investigated, among others, some flavanols like e.g. 
catechin.91 These compounds do not show a neuroprotection in the same assay, whereas 
kaempferol and eriodictyol do (Kling et al. 2013). With regard to the corresponding 
structures, the additional carbonyl moiety at C-4 seems to play the crucial role (Figure 62). A 
free hydroxyl function at position 3, as well as a catechol moiety at the B-ring or a C2-C3 
double bond are not sufficient for the activity. 
 
  
Figure 62: Structures of flavonoids tested in the neuroprotection assay (Kling et al., 2013). 
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Compound Trolox 
equivalents 
SD 
Kaempferol 4.8 ± 0.5 
Kaempferol-3-O-                    
-D-glucuronide 
2.3 ± 0.2 
Kaempferol-7-O-                    
-D-glucuronide 
3.2 ± 0.3 
Kaempferol-4´-O-                    
-D-glucuronide 
1.3 ± 0.2 
Kaempferol-7,4´-di-O-          
-D-glucuronide 
1.0 ± 0.1 
Kaempferol-7-sulfate 2.0 ± 0.2 
 
Table 41: Oxygen radical absorbance capacity (ORAC, Trolox equiv,  
1-5 µM) by kaempferol and the synthesized conjugates 
5.3.2 ORAC-Fluorescein Assay 
The antioxidant capacities of kaempferol, kaempferol-7-sulfate, kaempferol-3-O-                    
-D-glucuronide, kaempferol-7-O--D-glucuronide, kaempferol-4´-O--D-glucuronide and 
kaempferol-7,4´-di-O--D-glucuronide were investigated in relation to Trolox for the free 
radical generating compound 2,2'-azobis(2-
amidinopropane) dihydrochloride (AAPH). Kaempferol 
showed with a value of 4.8 the highest radical 
scavenging effect (Table 41), which is based in the 
presence of theoretically four oxidizable hydroxyl 
functions. Principally, a substitution with a sulfate- or 
glucuronic acid moiety does reduce the electron density in the aromatic system and results 
in a lower oxidizability. It can be expected that just the hydroxyl functions at position 3 and 
4´ are oxidized (Figure 63),27 which explains the lower antioxidant capacity, if a glucuronic 
acid is substituted to 3-OH or 4´-OH. 
Consequently, among the 
synthesized monoglucuronides, 
kaempferol-7-O--D-glucuronide 
had with a value of 3.2 the highest 
anti-oxidant activity. Also 
concerning kaempferol-7-sulfate, an 
oxidation at the B- and C- ring is 
possible and thus, the Trolox 
equivalent is at a medium value 
regarding the investigated 
compounds.  
The anti-oxidant activity of kaempferol in relation to Trolox was also analyzed by Guo et al. 
to a value of 2.67 ± 0.13.92 In this study, also AAPH was used for the free radical generating, 
but R-Phycoerythrin as indicator. The fact that we have applied fluorescein to monitor the 
radical attack and that the instrument setup is partly different can explain the variation in 
the obtained values. Nevertheless, a significant anti-oxidant activity of kaempferol cannot be 
denied.  
Figure 63: Oxidized form of kaempferol 
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5.3.3 ICAM-1 Expression 
The glucuronide and the sulfate conjugates of kaempferol did not show any decrease in 
ICAM-1 expression in the tested concentration range (up to 50 µM, Scheme 5). For the 
aglycone a certain effect was detected, but not in a significant manner. Regarding that the 
anti-inflammatory activity can be based on several pathways, some other assays with regard 
to further inflammation pathways have do be considered. 
The biological relevance of the glucuronides might be more imported in vivo due to 
deglucuronidation during inflammation, which was already shown for luteolin.20 The -
glucuronidase activity increases in rat plasma after the injection of pro-inflammatory 
lipopolysaccharide (LPS).93 During the inflammation process, -glucuronidase is known be 
released by neutrophil granulocytes.94 Along with the release of -glucuronidase a lower pH 
value of 4-5 at an inflammation side intensifies the enzyme activity.93 Kaempferol is known 
to inhibit moderate the LPS induced NF-κB activiation (∼60%, 100 µM),95 which is an 
intersection point with the TNF-α induced expression of ICAM-1 in the present study, 
wherein also NF-κB is a necessary transcription factor. 
 
Scheme 5: Inhibition of ICAM-1 expression of kaempferol and some conjugates 
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c (Kaempferol)  
[µM] 
% Cell Control 
5 76.4 
25 36.7 
50 9.7 
 
Table 42: Anti-proliferative activity of Kaempferol 
5.3.4 Proliferation Assay 
Kaempferol showed a concentration dependent anti-proliferativ activity on HMEC-1 cells. 
This effect possibly based on the already described reduction of Vascular Endothelial Growth 
Factor (VEGF) gene expression.96 A VEGF isoform is known to induce angiogenic processes in 
HMEC cells in biomimetic hydrogels, which 
includes increased cell proliferation, migration, 
and survival of apoptosis. A comparable study 
from the literature showed also inhibition of cell 
proliferation in HMEC cells of some flavonoids 
wherein the activity at 50 µM was as follows: quercetin (∼40% of control) > naringenin 
(∼70% of control) > catechin (comparable to control).97 Of course is has to be considered, 
that the assay setup is not exactly the same, but in combination with the published data 
some structural key elements can be estimated. The C2-C3 double bond and the C4 keto 
function seem to play a crucial role, whereas a catechol moiety or a hydroxyl function at C3 
have no strong effect. But of course, further data of this assay concering a wide range of 
different flavonoids are necessary to verify this theory. 
Although kaempferol has anti-angiogenetic and thus anti-proliferative activity against 
several tumor cell lines regarding, i.e. ovarian- ,96 breast-98 and pancreatic-99 cell lines, it is 
widely discussed in literature, whether flavonoids would be suitable for the 
chemoprevention of certain cancerogenic deseases. 
In contrast, the tested kaempferol-4´-O--D-glucuronide, kaempferol-7,4-di-O--D-
glucuronide and the kaempferol-7-sulfate did not show anti-proliferative activity in this 
assay (80-104% of control). In this context also the deglucuronidation may play a certain role 
in vivo. Tumours have a high metabolic rate and thus a acidosis is a possible consequence.100 
As mentioned above, a pH value of 4-5 intensifies the activity of -glucuronidase and 
therefore a liberation of free kaempferol. 
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6 Summary 
Flavonoids are secondary metabolites and almost ubiquitous in many edible plants and thus 
part of a healthy nutrition. They can be found mainly as glycosides in fruits and other 
vegetables, but also in some herbal medicines like Tebonin®, which active ingredient is an 
extract from the leaves of Ginkgo biloba. Following to the oral ingestion, these flavonoid 
glycosides are hydrolyzed in the small intestine. After absorption to the epithelium, the 
generated aglycone can be conjugated for instance with methyl-, sulfate- or glucuronic acid 
groups (phase-II-metabolism). This derivatisation initialize the excretion via kidney or bile 
but also results in a distribution of these metabolites in the body via the blood circulation. 
Consequently these flavonoid derivatives have the ability to reach several organs and 
tissues. 
Flavonoids are known to have many benefical effects on health, but whether just the 
aglycones or also the in vivo conjugates are responsible is not always obvious. These is partly 
based in the lack of knowledge concerning the in vivo status of the metabolites in the 
tissues. The questions arises whether conjugates or maybe deconjugated metabolites are 
substrates for certain enzymes in tissues or organs. 
In this work, the main phase-II-metabolites of kaempferol glycosides were identified and 
quantified in rat plasma. To achive this, the expected metabolites were chemically 
synthesized and used as reference substance in HPLC analysis. The different kaempferol 
glycosides for oral application were isolated from flavonol-enriched fractions of the Ginkgo 
folium extract EGb 761® obtained from Dr. Willmar Schwabe GmbH & Co. KG. Single 
kaempferol glycosides were orally administred to male Spraque Dawley rats, respectively. 
Finally, kaempferol-3-O--D-glucuronide, kaempferol-7-O--D-glucuronide and a kaempferol 
glucuronide-sulfate could be identified as the main metabolites after oral application of 
kaempferol rutinoside to rats. 
The pharmacological investigation of kaempferol and some synthezised derivatives by the 
neuroprotectivity/neurotoxicity assay, but especially by the ORAC assay, confirmed the 
frequently mentioned anti-oxidative activity, wherein the aglycone showed the highest 
capacity. Also an anti-proliferative activity was detected for kaempferol, whereas the 
conjugates did not show any significant activity in this cell based assay. Similar results were 
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obtained for the inhibition of ICAM-1 expression were just the aglycone showed a weak 
activity.  
7 Zusammenfassung 
Flavonoide sind sekundäre Metabolite in Pflanzen und somit unter anderem Bestandteil 
einer gesunden Ernährung. In Gemüse und Früchten kommen vor allem die Glycoside dieser 
Verbindungen vor. Weiterhin findet man Flavonoide in vielen Phytopharmaka wie 
beispielsweise Tebonin®, dessen aktiver Inhaltsstoff ein Extrakt aus Ginkgo biloba Blättern 
darstellt. Nach oraler Aufnahme werden diese Flavonoidglycoside im Dünndarm hydrolisiert 
und können über das Dünndarmepithel aufgenommen werden. Der Aufnahme schließt sich 
eine Derivatisierung an, d.h. die entstandenen Aglykone werden z.B. mit einer Methyl-, 
Sulfat- oder Glucuronsäure-Gruppe konjugiert (Phase-II-Metabolismus). Der Grund für diese 
Substitution liegt grundsätzlich darin, die Substanz für die Exkretion über Niere oder Galle 
zugänglich zu machen, führt aber auch zu einer Aufnahme und Verteilung der Metabolite 
über den Blutkreislauf. Somit sind diese Verbindungen in der Lage zahlreiche Organe und 
Gewebe des Körpers erreichen. 
Einige gesundsheitsfördernde Eigenschaften von Flavonoiden wurden bereits gezeigt, aber 
ob diese Effekte auf das Aglykon oder auch auf die Phase-II-Metabolite zurückzuführen sind 
ist bisher nicht eindeutig geklärt. Dies liegt unter anderem auch daran, dass in-vivo nicht 
genau bekannt ist, ob und vor allem in welchem Ausmaß die Konjugate in den Geweben 
wieder zu den Aglykonen umgesetzt werden. 
In dieser Arbeit wurden die wichtigsten Phase-II-Metabolite von verschiedenen 
Kämpferolglykosiden im Plasma von Ratten identifiziert und quantifiziert. Um dies zu 
ermöglichen, wurden die erwarteten Metabolite chemisch synthesiert und als 
Referenzsubstanzen für die HPLC-Analyse genutzt. Für die orale Applikation wurden vier 
Kämpferolglycoside aus mit Flavonolen angereicherten Fraktionen des Ginkgo folium 
Extraktes EGb 761® isoliert, welche von der Dr. Willmar Schwabe GmbH & Co. KG 
bereitgestellt wurden. Nach oraler Applikation der Glykoside an männliche Spraque Dawley 
Ratten konnten Kämpferol-3-O--D-glucuronid, Kämpferol-7-O--D-glucuronid and ein 
Kämpferol Glucuronid/Sulfat als Hauptmetabolite identifiziert bzw. nach der Gabe von 
Kämpferolrutinosid auch teilweise quantifiziert werden. 
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Die Untersuchung von Kämpferol und einiger der synthetisierten Phase-II-Metabolite mittels 
des Neuroprotektivität/Neurotoxizität Assays, aber vor allem des ORAC Assays, bestätigte 
die oftmals erwähnte antioxidative Aktivität, insbesondere bzgl. des Aglykons. Dieses zeigt 
sowohl antiproliferative Eigenschaften als auch eine schwache Hemmung der ICAM-1 
Expression. Die synthetisierten Konjugate des Kämpferols zeigten dagegen keine signifikante 
Aktivität in einem der durchgeführten zellbasierten Assays. 
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